Advance

IWASA Tsutomu

    Department of Medicine　Lecturer
Last Updated :2024/04/25

Researcher Information

Degree

  • MD. Ph.D（2010/03 Kindai University）

J-Global ID

Research Areas

  • Life sciences / Genomics
  • Life sciences / Tumor diagnostics and therapeutics
  • Life sciences / Tumor biology
  • Life sciences / Internal medicine - General

Academic & Professional Experience

  • 2014/04 - Today  Kindai University, Faculty of MedicineDepartment of Medical OncologyLucture
  • 2012/09 - 2014/03  Kindai University, Faculty of MedicineDepartment of Medical OncologyAssistant professor
  • 2010/07 - 2012/08  Dana-Farber Cancer InstitutePosdoc fellow
  • 2010/05 - 2010/06  Kindai University, Faculty of MedicineDepartment of Medical OncologyAssistant professor
  • 2009/04 - 2010/04  National Hospital Organization Minami Wakayama Medical CenterDepartment of respiratory medicineStaff
  • 2003/04 - 2008/03  Kindai University, Faculty of MedicineDepartment of Medical OncologyAssistant Professor

Education

  • 2005/04 - 2008/03  Kindai University, Faculty of Medicine  Graduate school of Medical science, Department of Medical Oncology
  • 1997/04 - 2003/03  Kindai University, Faculty of Medicine

Association Memberships

  • THE JAPANESE RESPIRATORY SOCIETY   日本乳癌学会   日本臨床腫瘍学会   THE JAPANESE SOCIETY OF INTERNAL MEDICINE   

Published Papers

  • Hidetoshi Hayashi; Kenji Chamoto; Ryusuke Hatae; Takashi Kurosaki; Yosuke Togashi; Kazuya Fukuoka; Megumi Goto; Yasutaka Chiba; Shuta Tomida; Takayo Ota; Koji Haratani; Takayuki Takahama; Junko Tanizaki; Takeshi Yoshida; Tsutomu Iwasa; Kaoru Tanaka; Masayuki Takeda; Tomoko Hirano; Hironori Yoshida; Hiroaki Ozasa; Yuichi Sakamori; Kazuko Sakai; Keiko Higuchi; Hitoshi Uga; Chihiro Suminaka; Toyohiro Hirai; Kazuto Nishio; Kazuhiko Nakagawa; Tasuku Honjo
    Journal of Clinical Investigation American Society for Clinical Investigation 134 (7) 2024/04
  • 治療前CD163はニボルマブ+化学療法における予後不良因子(WJOG9917BTR)
    尾崎 由記範; 岩朝 勤; 北野 滋久; 山下 万貴子; 鶴谷 純司; 高橋 將人; 向原 徹; 増田 慎三; 二村 学; 南 博信; 松本 光史; 田辺 裕子; 川端 英孝; 吉村 健一; 高野 利実
    日本癌治療学会学術集会抄録集 (一社)日本癌治療学会 61回 O25 - 3 2023/10
  • Hiroko Masuda; Yuko Tanabe; Hitomi Sakai; Koji Matsumoto; Akihiko Shimomura; Mihoko Doi; Yasuo Miyoshi; Masato Takahashi; Yasuaki Sagara; Shinya Tokunaga; Tsutomu Iwasa; Naoki Niikura; Kenichi Yoshimura; Toshimi Takano; Junji Tsurutani
    Breast (Edinburgh, Scotland) 71 22 - 28 2023/10 
    BACKGROUND: Abemaciclib-induced diarrhea (AID) impairs quality of life (QOL) and treatment adherence in patients with breast cancer. Supportive treatment with loperamide is associated with constipation. We hypothesized that probiotics and trimebutine maleate (TM) would decrease the frequency of AID without causing constipation. METHODS: Hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer patients were randomized into the probiotic Bifidobacterium (A) or probiotic Bifidobacterium and TM (B) groups. Endocrine therapy, Abemaciclib and probiotic Bifidobacterium three times a day for 28 days, was administered to both arms. Arm B was treated with TM upon the onset of diarrhea. The primary endpoint was the percentage of patients who experienced grade ≥2 diarrhea. The secondary endpoints were safety, frequency, and duration of all-grade diarrhea; frequency of emesis and constipation; usage of loperamide; and health-related QOL/patient-reported outcome during the study. We evaluated whether the primary endpoint of each arm exceeded the predetermined threshold. RESULTS: Fifty-one patients completed treatment. Grade 2 diarrhea occurred in 52% and 50% of patients in Arm A and Arm B, respectively. One patient experienced grade 3 diarrhea in each arm. The median duration of grade2 diarrhea was 2 and 2.5day, and only one patient required dose reduction. Grade ≥2 constipation was observed in 4% of Arm A and 3.6% of Arm B. CONCLUSIONS: Probiotic Bifidobacterium or the combination of probiotic Bifidobacterium with TM did not decrease the incidence of grade 2 or greater diarrhea compared with historical control, although the grade 3 or greater diarrhea was reduced. CLINICAL TRIAL REGISTRATION: jRCT (Japan registry of clinical trials). jRCTs031190154.
  • Jun Masuda; Hitomi Sakai; Junji Tsurutani; Yuko Tanabe; Norikazu Masuda; Tsutomu Iwasa; Masato Takahashi; Manabu Futamura; Koji Matsumoto; Kenjiro Aogi; Hiroji Iwata; Mari Hosonaga; Toru Mukohara; Kiyoshi Yoshimura; Chiyo K Imamura; Sakiko Miura; Toshiko Yamochi; Hidetaka Kawabata; Hiroyuki Yasojima; Nobumoto Tomioka; Kenichi Yoshimura; Toshimi Takano
    Journal for ImmunoTherapy of Cancer BMJ 11 (9) e007126 - e007126 2023/09 
    Background Hormone receptor (HR)-positive breast cancer is a disease for which no immune checkpoint inhibitors have shown promise as effective therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors synergistically increased the effectiveness of antiprogrammed cell death protein-1 (anti-PD-1)/programmed death-ligand 1 (PD-L1) antibodies in preclinical studies. Methods This non-randomized, multicohort, phase II study evaluated the efficacy and safety of the anti-PD-1 antibody nivolumab 240 mg administered every 2 weeks in combination with the CDK4/6 inhibitor abemaciclib 150 mg twice daily and either fulvestrant (FUL) or letrozole (LET) as a first-line or second-line treatment for HR-positive HER2-negative metastatic breast cancer. The primary end point was the objective response rate (ORR), and secondary end points were toxicity, progression-free survival, and overall survival. Blood, tissue, and fecal samples were collected at multiple points for correlative studies to evaluate immunity biomarkers. Results From June 2019 to early study termination due to safety concerns on July 2020, 17 patients were enrolled (FUL: n=12, LET: n=5). One patient with a prior treatment history in the FUL cohort was excluded. ORRs were 54.5% (6/11) and 40.0% (2/5) in the FUL and LET cohorts, respectively. Treatment-emergent (TE) adverse events (AEs) of grade ≥3 occurred in 11 (92%) and 5 (100%) patients in the FUL and LET cohorts, respectively. The most common grade ≥3 TEAEs were neutropenia (7 (58.3%) and 3 (60.0%) in the FUL and LET cohorts, respectively), followed by alanine aminotransferase elevation (5 (41.6%) and 4 (80.0%)). One treatment-related death from interstitial lung disease occurred in the LET cohort. Ten patients developed liver-related grade ≥3 AEs. Liver biopsy specimens from 3 patients showed hepatitis characterized by focal necrosis with predominant CD8+ lymphocyte infiltration. Marked elevation of tumor necrosis factor-related cytokines and interleukin-11, and a decrease in peripheral regulatory T cells (Tregs), were observed in patients with hepatotoxicity. These findings suggest that treatment-related toxicities were immune-related AEs likely caused by proinflammatory cytokine production and suppression of Treg proliferation due to the addition of abemaciclib to nivolumab therapy. Conclusions Although the combination of nivolumab and abemaciclib was active, it caused severe and prolonged immune-related AEs. Trial registration number JapicCTI-194782, jRCT2080224706, UMIN000036970.
  • HER2陰性転移再発乳癌に対するニボルマブ+ベバシズマブ+パクリタキセル併用療法の第II相試験(WJOG9917B)
    尾崎 由記範; 鶴谷 純司; 向原 徹; 岩朝 勤; 高橋 將人; 田辺 裕子; 川端 英孝; 増田 慎三; 二村 学; 南 博信; 松本 光史; 吉村 健一; 北野 滋久; 高野 利実
    日本乳癌学会総会プログラム抄録集 (一社)日本乳癌学会 31回 65 - 65 2023/06
  • 再発乳癌とstage IV乳癌における免疫状態や免疫チェックポイント阻害薬に対する反応性の違い WJOG9917BTR
    尾崎 由記範; 北野 滋久; 山下 万貴子; 五十嵐 大樹; 鶴谷 純司; 岩朝 勤; 高橋 將人; 向原 徹; 増田 慎三; 二村 学; 南 博信; 松本 光史; 田辺 裕子; 川端 英孝; 吉村 健一; 高野 利実
    日本乳癌学会総会プログラム抄録集 (一社)日本乳癌学会 31回 73 - 73 2023/06
  • Hitomi Sakai; Junji Tsurutani; Yukinori Ozaki; Hiroshi Ishiguro; Kazuki Nozawa; Kenichi Watanabe; Shigeto Maeda; Takamichi Yokoe; Chiyo K Imamura; Koji Matsumoto; Tsutomu Iwasa; Yasutaka Chiba; Daisuke Takiguchi; Toshimi Takano
    BMJ Open BMJ 13 (4) e070304 - e070304 2044-6055 2023/04 
    Introduction The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) has led to a change in the clinical management of breast cancer. Nausea and vomiting are the most common adverse events of T-DXd, which cannot be completely alleviated by standard prophylactic regimens. Olanzapine is particularly effective in preventing delayed nausea caused by chemotherapy. In this study, we will evaluate the efficacy of olanzapine in managing persistent nausea and vomiting during T-DXd treatment. Methods and analysis The ERICA study is a multicentre, placebo-controlled, double-blind, randomised phase II study with the aim to evaluate the antiemetic effects of the prophylactic olanzapine (5 mg orally, on days 1–6) or placebo combined with a 1,5-hydroxytryptamine-3 (5-HT3)–receptor antagonist and dexamethasone in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer undergoing T-DXd treatment. For a period of 22 days from the day of T-DXd treatment, patients will document their experience in an electronic symptom diary daily during observational periods. The primary endpoint is the complete response rate, defined as no vomiting and no rescue medications during the ‘delayed phase’ of 24–120 hours post-T-DXd administration. In addition, we define 120–504 hour as the ‘persistent phase’ and 0–504 hours as the ‘overall phase’ for secondary endpoint analysis. We have estimated that a total sample size of at least 156 patients is needed to allow a power of 80% at a one-sided significance level of 20% in this study. The target sample size is set to 166 to account for possible case exclusions. Ethics and dissemination The study protocol is approved by the West Japan Oncology Group protocol review committee and the SHOWA University Clinical Research Review Board. The study results will be presented at international conferences and published in a peer-reviewed journal. Trial registration number jRCTs031210410.
  • Hiroji Iwata; Rikiya Nakamura; Norikazu Masuda; Toshinari Yamashita; Yutaka Yamamoto; Kokoro Kobayashi; Junji Tsurutani; Tsutomu Iwasa; Kan Yonemori; Kenji Tamura; Tomoyuki Aruga; Eriko Tokunaga; Koji Kaneko; Min-Jung Lee; Akira Yuno; Azusa Kawabata; Toshihiro Seike; Ayumi Kaneda; Yozo Nishimura; Jane B Trepel; Shigehira Saji
    Japanese journal of clinical oncology 53 (1) 4 - 15 2023/01 
    BACKGROUND: We aimed to confirm the efficacy and safety of the oral histone deacetylase inhibitor entinostat in Japanese patients with hormone receptor-positive advanced/recurrent breast cancer and to explore potential biomarkers. METHODS: This phase II, double-blind, randomized, placebo-controlled trial (ClinicalTrials.gov; NCT03291886) was conducted at 28 Japanese sites (September 2017-July 2020; interim analysis cutoff: April 2019). Patients with progression/relapse following non-steroidal aromatase inhibitors were randomized 1:1 to entinostat (5 mg/week) or placebo, plus exemestane (25 mg/day). Primary endpoint was progression-free survival; secondary endpoints included overall survival and safety. Exploratory biomarker outcomes included lysine acetylation, immune cell profiles, estrogen receptor 1 mutations and plasma chemokines. RESULTS: Of 133 randomized patients, 131 (65 entinostat, 66 placebo) who received study drug were analyzed. Median (95% confidence interval) progression-free survival was 5.8 (3.2-7.8) months for entinostat and 3.3 (3.1-5.8) months for placebo (hazard ratio [95% confidence interval]: 0.75 [0.50 - 1.14]; P = 0.189). Median overall survival was not reached in either group. Entinostat tended to prolong progression-free survival in patients aged ≥65 years, not endocrine resistant, or with estrogen receptor 1 Y537S mutation. Candidate biomarkers of efficacy (progression-free survival) included lysine acetylation in CD3+ cells, plasma interferon gamma-induced protein 10, dendritic cell CD86 expression, and CD4+ cell expression of human leukocyte antigen-DR and inducible T-cell co-stimulator. Safety was similar to non-Japanese populations; however, seven entinostat-treated patients (10.8%) had reversible lung injury. CONCLUSIONS: In Japanese patients, the safety of entinostat plus exemestane was acceptable and progression-free survival was prolonged, although not significantly. Exploratory analyses identified potential biomarkers, including lysine acetylation, of efficacy.
  • Yuko Abe; Naruto Taira; Kosuke Kashiwabara; Junji Tsurutani; Masahiro Kitada; Masato Takahashi; Hiroaki Kato; Yuichiro Kikawa; Eiko Sakata; Yoichi Naito; Yoshie Hasegawa; Tsuyoshi Saito; Tsutomu Iwasa; Tsutomu Takashima; Tomohiko Aihara; Hirofumi Mukai; Fumikata Hara; Tadahiko Shien; Hiroyoshi Doihara; Shinichi Toyooka
    Acta medica Okayama 76 (6) 661 - 671 2022/12 
    Chemotherapy-induced peripheral neuropathy (CIPN) is an important clinical challenge that threatens patients' quality of life. This sub-study of the ABROAD trial investigated the influence of single nucleotide polymorphisms (SNPs) on CIPN, using genotype data from a randomized study to determine the optimal dose of a 3-week-cycle regimen of nab-paclitaxel (q3w nab-PTX) in patients with metastatic breast cancer (MBC). Patients with HER2-negative MBC were randomly assigned to three doses of q3w nab-PTX (SD: 260 mg/m2 vs. MD: 220 mg/m2 vs. LD: 180 mg/m2). Five SNPs (EPHA4-rs17348202, EPHA5-rs7349683, EPHA6-rs301927, LIMK2-rs5749248, and XKR4-rs4737264) were analyzed based on the results of a previous genome-wide association study. Per-allele SNP associations were assessed by a Cox regression to model the cumulative dose of nab-PTX up to the onset of severe or worsening sensory neuropathy. A total of 141 patients were enrolled in the parent study; 91(65%) were included in this sub-study. Worsening of CIPN was significantly greater in the cases with XKR4 AC compared to those with a homozygote AA (HR 1.86, 95%CI: 1.00001-3.46, p=0.049). There was no significant correlation of CIPN with any other SNP. A multivariate analysis showed that the cumulative dose of nab-PTX was most strongly correlated with CIPN (p<0.01).
  • Yukinori Ozaki; Junji Tsurutani; Toru Mukohara; Tsutomu Iwasa; Masato Takahashi; Yuko Tanabe; Hidetaka Kawabata; Norikazu Masuda; Manabu Futamura; Hironobu Minami; Koji Matsumoto; Kenichi Yoshimura; Shigehisa Kitano; Toshimi Takano
    Data in brief 45 108558 - 108558 2022/12 
    The purpose was to explore potential biomarkers of the efficacy and toxicity of triple therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Tumor tissues before treatment and blood samples at pretreatment, during and after treatment were collected. The serum samples were used to measure the concentrations of cytokines. Progression-free survival (PFS), overall survival (OS), and response were analyzed in association with the biomarker data using the Kaplan-Meier method and log-rank tests. Fifty patients were included in the biomarker analysis. Programmed death-ligand 1 (PD-L1) expression on tumor cells and immune cells were evaluated in tumor tissue samples using a Dako 28-8 immunohistochemistry assay and using a VENTANA SP142 immunohistochemistry assay. PD-L1 positive rates using anti-PD-L1 antibodies 28-8 (Combined positive score [CPS] ≥1) and SP142 (Immune cells [IC] ≥1) were 15% and 17%, respectively. The PFS and OS were not significantly different in the subgroups by PD-L1 expression. The median pretreatment vascular endothelial growth factor (VEGF)-A concentration was 116.1 pg/ml (range 0-740.23 pg/ml) on day 1 and decreased to <37 pg/ml on day 8 of cycle 1 in all patients. Subtypes (hormone receptor-positive HER2-negative or triple negative breast cancer), stage (recurrent or de novo stage IV) and liver metastasis (yes or no) were not significantly different between patients in VEGF-A high and VEGF-A low groups. PFS in the VEGF-A high group was similar to that in the VEGF-A low group.
  • Toshio Shimizu; Kazuhiko Nakagawa; Hidetoshi Hayashi; Tsutomu Iwasa; Hisato Kawakami; Satomi Watanabe; Noboru Yamamoto; Kan Yonemori; Takafumi Koyama; Jun Sato; Kenji Tamura; Keiichi Kikuchi; Kenichiro Akaike; Shiho Takeda; Masayuki Takeda
    Investigational new drugs 41 (1) 1 - 12 2022/11 
    To determine the maximum tolerated dose (MTD) and recommended dose (RD) of orally-administered bendamustine in Japanese patients with advanced solid tumors. The optimal dosing schedule, safety, pharmacokinetics, and preliminary antitumor effects were also evaluated. A multicenter, open-label trial with a standard 3 + 3 design and dose escalation by dose-limiting toxicity (DLT) was conducted. The treatment schedules were once daily for 7, 14, and 21 days every 3 weeks as one cycle. The total dose per cycle was increased from 175 to 840 mg/m2. Eighteen patients were enrolled in this study. DLT occurred in one of six patients at 75 mg/m2/day × 7 days, and one of three patients at 37.5 mg/m2/day × 14 days and 25 mg/m2/day × 21 days. However, the delayed recovery from a decrease in neutrophil or platelet count hampered the start of subsequent treatment cycles, and the trend was more prominent at 37.5 mg/m2/day × 14 days and 25 mg/m2/day × 21 days than in 75 mg/m2/day × 7 days. MTD was determined as 75 mg/m2/day × 7 days to allow acceptable hematologic recovery. The pharmacokinetics of orally-administered bendamustine were generally dose-dependent; however, the inter-individual variability is relatively large. The major adverse events were hematologic toxicities; gastrointestinal disorders were generally mild. Adverse drug reactions did not lead to the discontinuation of the drug. A partial response was observed in two of six patients (prostatic small cell carcinoma and thymic carcinoma) at 75 mg/m2/day × 7 days. The RD and optimal dosing schedule of orally-administered bendamustine was 75 mg/m2 once daily for 7 days every 3 weeks for the treatment of advanced solid tumors. (Trial registration number ClinicalTrials.gov NCT03604679. Registration date July 27, 2018).
  • Kohsuke Isomoto; Koji Haratani; Takahiro Tsujikawa; Yusuke Makutani; Hisato Kawakami; Masayuki Takeda; Kimio Yonesaka; Kaoru Tanaka; Tsutomu Iwasa; Hidetoshi Hayashi; Akihiko Ito; Kazuto Nishio; Kazuhiko Nakagawa
    Lung cancer (Amsterdam, Netherlands) 174 71 - 82 2022/10 
    OBJECTIVE: Immune checkpoint inhibitors (ICIs) have become a key therapeutic modality for advanced non-small cell lung cancer (NSCLC), but most patients experience primary or acquired resistance to these drugs. We here explored the mechanisms underlying both types of ICI resistance by analysis of the tumor immune microenvironment (TME). MATERIALS AND METHODS: Four patients who experienced a long-term response to ICI treatment (progression-free survival [PFS] of ≥12 months) followed by disease progression, after which a rebiopsy was immediately performed (cohort-A), as well as four patients who experienced early tumor progression during ICI treatment (PFS of <9 weeks, cohort-B) were enrolled in this retrospective study. The pretreatment TME was evaluated by 16- or 17-color multiplex immunohistochemistry (mIHC)-based spatial profiling at the single-cell level for both cohorts. In cohort-A, changes in the TME after disease progression during ICI treatment were also investigated by mIHC analysis and transcriptomic analysis. RESULTS: Pretreatment tumor tissue from cohort-B manifested poor infiltration of tumor-reactive CD8+ T cells characterized by CD39 and CD103 expression or by programmed cell death-1 expression, implicating insufficient recognition of tumor cells by CD8+ T cells as a mechanism of primary ICI resistance. Analysis of the paired tumor specimens from cohort-A revealed various changes in the TME associated with acquired ICI resistance, including substantial infiltration of myeloid-derived suppressor cells and M2-type tumor-associated macrophages without a marked decline in the number of tumor-reactive CD8+ T cells; a decrease in the number of tumor-reactive CD8+ T cells; and an apparent decrease in neoantigen presentation by tumor cells. CONCLUSION: The presence of intratumoral tumor-reactive CD8+ T cells may be a prerequisite for a long-term response to ICI treatment in advanced NSCLC, but it is not sufficient for cancer cell eradication. Various TME profiles are associated with acquired ICI resistance, suggesting that patient-specific strategies to overcome such resistance may be necessary.
  • Yukinori Ozaki; Junji Tsurutani; Toru Mukohara; Tsutomu Iwasa; Masato Takahashi; Yuko Tanabe; Hidetaka Kawabata; Norikazu Masuda; Manabu Futamura; Hironobu Minami; Koji Matsumoto; Kenichi Yoshimura; Shigehisa Kitano; Toshimi Takano
    European journal of cancer (Oxford, England : 1990) 171 193 - 202 2022/08 
    BACKGROUND: Preclinical models revealed potential synergistic effects of programmed cell death-1 inhibitors and anti-vascular endothelial growth factor (VEGF) antibodies. Therefore, we investigated the use of nivolumab, bevacizumab, and paclitaxel triple therapy for metastatic breast cancer. METHODS: This phase 2, multicentre, single-arm study (NEWBEAT) investigated the safety and efficacy of first-line nivolumab, paclitaxel, and bevacizumab in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer, regardless of programmed cell death-ligand 1 expression. The primary end-point was objective response rate. Key secondary end-points included progression-free survival, overall survival, and toxicities. A biomarker study evaluated tumour programmed cell death-ligand 1 expression and serum VEGF-A levels. RESULTS: Between February 2018 and October 2018, 57 patients were enrolled. An objective response rate was seen in 39/56 patients (70%, 95% confidence interval [CI]: 55.9-81.2%), meeting the primary end-point. The objective response rate was 74% in patients with hormone receptor-positive breast cancer versus 59% in patients with triple-negative breast cancer. The median progression-free survival and overall survival were 14.0 (95% CI 11.0-16.3) and 32.5 (95% CI 26.0-not evaluable) months, respectively (median follow-up: 29.5 months). Grade 3/4 adverse drug reactions occurred in 33 of 57 patients (58%). There were no grade 5 adverse events. Immune-related adverse events occurred in 43 of 57 patients (75%), with grade 3/4 events in eight patients (14%). Biomarker analysis showed that tumour programmed cell death-ligand 1 expression was not correlated with the efficacy of triple therapy. Efficacy outcomes were similar between the serum VEGF-high and VEGF-low groups. CONCLUSIONS: First-line nivolumab, bevacizumab, and paclitaxel therapy showed promising efficacy and manageable toxicity in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
  • HER2+ mBC患者を対象としたT-DXd投与中のCINVに対するオランザピン投与の第II相試験 WJOG14320B(ERICA)(Phase II study of olanzapine for CINV during T-DXd in HER2+ mBC patients: WJOG14320B(ERICA))
    酒井 瞳; 鶴谷 純司; 横江 隆道; 今村 知世; 松本 光史; 岩朝 勤; 千葉 康敬; 平川 雄士; 高野 利実
    日本乳癌学会総会プログラム抄録集 (一社)日本乳癌学会 30回 EP17 - 4 2022/06
  • Meiko Nishimura; Takahiro Kogawa; Yuko Akaishi; Misato Ogata; Jun Masuda; Mitsuo Terada; Hitomi Sakai; Kazuki Nozawa; Sasagu Kurozumi; Takamichi Yokoe; Yukinori Ozaki Ozaki; Shu Yazaki; Mai Onishi; Tsutomu Iwasa; Takuma Onoe; Yuta Okumura; Sayaka Nakayama; Kanako Hagio; Yuko Takahashi; Hirokazu Tanino; Junji Tsurutani; Koji Matsumoto; Mototsugu Shimokawa; Toshimi Takano
    CANCER RESEARCH AMER ASSOC CANCER RESEARCH 82 (4) 0008-5472 2022/02
  • Kohsuke Isomoto; Koji Haratani; Satomi Watanabe; Masayuki Takeda; Tsutomu Iwasa; Kazuhiko Nakagawa
    Investigational new drugs 40 (1) 194 - 197 2022/02 
    Extramammary Paget disease (EMPD) is a rare cutaneous adenocarcinoma that usually is of epidermal origin and shows glandular differentiation and that is treated by wide local excision depending on the disease extent. For widely metastatic disease, however, a standard treatment remains to be established. Similar to breast cancer, EMPD has been found to overexpress human epidermal growth factor receptor 2 (HER2) or hormone receptors (HRs). Whereas HER2-directed therapy was recently shown to be effective for HER2-positive EMPD, the potential role of endocrine therapy for HR-positive EMPD has remained unknown. We here report a case of metastatic EMPD with HR positivity that was successfully treated with the selective estrogen receptor modulator tamoxifen. This first-line treatment of systemic metastasis resulted in durable tumor regression for > 20 months without any treatment-related toxicities. This is the first report to reveal the promise of tamoxifen as a safe and effective treatment for HR-positive metastatic EMPD.
  • Naruto Taira; Kosuke Kashiwabara; Junji Tsurutani; Masahiro Kitada; Masato Takahashi; Hiroaki Kato; Yuichiro Kikawa; Eiko Sakata; Yoichi Naito; Yoshie Hasegawa; Tsuyoshi Saito; Tsutomu Iwasa; Tsutomu Takashima; Tomohiko Aihara; Hirofumi Mukai; Fumikata Hara
    Breast cancer (Tokyo, Japan) 29 (1) 186 - 188 2022/01
  • 谷崎 潤子; 鈴木 慎一郎; 金村 宙昌; 岩朝 勤; 川上 尚人; 田中 薫; 吉田 健史; 米阪 仁雄; 伊藤 彰彦; 坂井 和子; 木寺 康裕; 福岡 和也; 千葉 康敬; 西尾 和人; 中川 和彦; 林 秀敏
    近畿大学医学雑誌 近畿大学医学会 46 (3-4) 20A - 20A 0385-8367 2021/12
  • 寺岡 俊輔; 赤松 弘朗; 林 秀敏; 藤本 大智; 早田 敦志; 原谷 浩司; 小澤 雄一; 吉田 健司; 岩朝 勤; 下川 敏雄; 富井 啓介; 中川 和彦; 山本 信之
    肺癌 (NPO)日本肺癌学会 61 (6) 498 - 498 0386-9628 2021/10
  • ベンダムスチン塩酸塩経口剤(SyB C-0501)の進行性固形がん患者に対する第1相臨床試験
    武田 真幸; 中川 和彦; 林 秀敏; 岩朝 勤; 川上 尚人; 渡邉 諭美; 山本 昇; 米盛 勧; 小山 隆文; 佐藤 潤; 田村 研治; 菊池 圭一; 赤池 健一郎; 竹田 志保; 清水 俊雄
    日本癌治療学会学術集会抄録集 (一社)日本癌治療学会 59回 O13 - 5 2021/10
  • 小細胞癌のICI(Treatment of SCLC) 再発小細胞肺がんに対するペムブロリズマブ+アムルビシンの多施設共同第II相試験
    寺岡 俊輔; 赤松 弘朗; 林 秀敏; 藤本 大智; 早田 敦志; 原谷 浩司; 小澤 雄一; 吉田 健司; 岩朝 勤; 下川 敏雄; 富井 啓介; 中川 和彦; 山本 信之
    肺癌 (NPO)日本肺癌学会 61 (6) 498 - 498 0386-9628 2021/10
  • Naruto Taira; Kosuke Kashiwabara; Junji Tsurutani; Masahiro Kitada; Masato Takahashi; Hiroaki Kato; Yuichiro Kikawa; Eiko Sakata; Yoichi Naito; Yoshie Hasegawa; Tsuyoshi Saito; Tsutomu Iwasa; Tsutomu Takashima; Tomohiko Aihara; Hirofumi Mukai; Fumikata Hara
    Breast cancer (Tokyo, Japan) 29 (1) 131 - 143 2021/09 
    BACKGROUND: To report our findings on quality of life (QoL) in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel (q3w nab-PTX) in patients with metastatic breast cancer (MBC). METHODS: Patients with HER2-negative MBC were randomly assigned to three different doses of q3w nab-PTX (SD 260 mg/m2 vs. MD: 220 mg/m2 vs. LD 180 mg/m2). QoL was assessed at baseline and during the second, fourth and sixth courses of treatment using the Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane), Cancer Fatigue Scale (CFS) and EuroQol 5-Dimension (EQ-5D). Comparisons were performed with mixed-model repeated measures (MMRM). RESULTS: A total of 141 patients were enrolled in the parent study, and 136 (96%) (44, 45 and 47 in the SD, MD, and LD groups) were included in the analysis. MMRM analysis showed that the difference from the baseline FACT-Taxane trial outcome index at MD and LD were significantly higher than that at SD (MD vs. SD P < 0.001, LD vs. SD P < 0.001). Differences from baseline for FACT-Taxane total, physical and emotional well-being, and taxane subscale scores at MD and LD were also higher than at SD. The difference from baseline for the CFS score at LD was lower than at SD (P = 0.013) and those for EQ-5D utility scores at MD and LD were higher than at SD (MD vs. SD P = 0.011, LD vs. SD P < 0.001). CONCLUSION: QoL of patients treated with 220 or 180 mg/m2 of q3w nab-PTX was significantly better than that of patients treated with 260 mg/m2. TRIAL REGISTRATION: The protocol was registered at the website of the University Hospital Medical Information Network (UMIN), Japan (protocol ID: UMIN000015516), on 01/11/2014. Details are available at the following address: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017916.
  • Hiroaki Akamatsu; Shunsuke Teraoka; Hidetoshi Hayashi; Daichi Fujimoto; Atsushi Hayata; Koji Haratani; Yuichi Ozawa; Takeshi Yoshida; Tsutomu Iwasa; Toshio Shimokawa; Keisuke Tomii; Kazuhiko Nakagawa; Nobuyuki Yamamoto
    JTO clinical and research reports 2 (7) 100184 - 100184 2021/07 
    INTRODUCTION: In patients with relapsed SCLC, amrubicin (AMR) is the current standard treatment in Japan. Nevertheless, its efficacy is not satisfactory and prognosis is poor. Preclinical study suggested that anthracycline agent might induce immunogenic cell death and work synergistically with immune checkpoint inhibitors. METHODS: Patients with relapsed SCLC who relapsed after completion of platinum-containing regimen were registered. Patients were treated with pembrolizumab (200 mg, flat dose on d 1, every 3 wk for 2 y) plus AMR (40 mg/m2 on d 1-3, every 3 wk until progression). Primary end point was overall response rate (ORR). Secondary end points consisted of progression-free survival (PFS), overall survival, and safety. On the basis of the hypothesis that this treatment will improve ORR from 20% to 40% (0.1 of one-sided α and power of 0.8), 25 patients are required (trial identifier: NCT03253068). RESULTS: Between November 2017 and October 2019, a total of 25 patients were enrolled. Most participants (88%) relapsed within 90 days after platinum-containing therapy and all patients were immune checkpoint inhibitor-naive. ORR, the primary end point, was 52.0% (95% confidence interval [CI]: 31.3%-72.2%). Median PFS was 4.0 months (95% CI: 2.8-7.0 mo), and PFS rate at 1 year was 14.4%. Median overall survival was 10.6 months (95% CI: 7.3-21.3 mo). Common adverse events greater than or equal to grade 3 were neutropenia (64%), leukopenia (40%), and febrile neutropenia (16%). No treatment-related deaths occurred. CONCLUSIONS: Among patients with relapsed SCLC, pembrolizumab plus AMR was effective and tolerable.
  • Junji Tsurutani; Fumikata Hara; Masahiro Kitada; Masato Takahashi; Yuichiro Kikawa; Hiroaki Kato; Eiko Sakata; Yoichi Naito; Yoshie Hasegawa; Tsuyoshi Saito; Tsutomu Iwasa; Naruto Taira; Tsutomu Takashima; Kosuke Kashiwabara; Tomohiko Aihara; Hirofumi Mukai
    Breast (Edinburgh, Scotland) 55 63 - 68 2021/02 
    BACKGROUND: Chemotherapy-induced peripheral neuropathy is commonly observed in patients treated with nanoparticle albumin-bound paclitaxel (nab-PTX). We conducted a multicenter randomized controlled study to evaluate the optimal dose of nab-PTX. METHODS: We compared three different doses of q3w nab-PTX (Standard: 260 mg/m2 [SD260] vs Medium: 220 mg/m2 [MD220] vs Low: 180 mg/m2 [LD180]) in patients with HER2-negative metastatic breast cancer (MBC). Primary endpoint was progression-free survival (PFS). Grade 3/4 neuropathy rates in the three doses were estimated using the logistic regression model. The optimal dose was selected in two steps. Initially, if the hazard ratio (HR) for PFS was <0.75 or >1.33, the inferior dose was excluded, and we proceeded with the non-inferior dose. Then, if the estimated incidence rate of grade 3/4 neurotoxicity exceeded 10%, that dose was also excluded. RESULTS: One hundred forty-one patients were randomly assigned to SD260 (n = 47), MD220 (n = 46), and LD180 (n = 48) groups, and their median PFS was 6.66, 7.34, and 6.82 months, respectively. The HRs were 0.73 (95% confidence interval [CI]: 0.42-1.28) in MD220 vs SD260, 0.77 (95% CI 0.47-1.28) in LD180 vs SD260, and 0.96 (95% CI 0.56-1.66) in LD180 vs MD220. SD260 was inferior to MD220 and was excluded. The estimated incidence rate of grade 3/4 neurotoxicity was 29.5% in SD260, 14.0% in MD220, and 5.9% in LD180. The final selected dose was LD180. CONCLUSIONS: Intravenous administration of low-dose nab-PTX at 180 mg/m2 q3w may be the optimal therapy with meaningful efficacy and favorable toxicity in patients with MBC.
  • Takamichi Yokoe; Sasagu Kurozumi; Kazuki Nozawa; Yukinori Ozaki; Tetsuyo Maeda; Shu Yazaki; Mai Onishi; Akihiro Fujimoto; Sayuka Nakayama; Yuko Tsuboguchi; Tsutomu Iwasa; Hitomi Sakai; Misato Ogata; Mitsuo Terada; Meiko Nishimura; Takuma Onoe; Jun Masuda; Michiko Kurikawa; Hirotsugu Isaka; Kanako Hagio; Akihiko Shimomura; Yuta Okumura; Manabu Futamura; Mototsugu Shimokawa; Toshimi Takano
    Breast Cancer Springer Science and Business Media LLC 1340-6868 2021/01 
    Abstract Background Trastuzumab emtansine (T-DM1) treatment for human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer after taxane with trastuzumab and pertuzumab is standard therapy. However, treatment strategies beyond T-DM1 are still in development with insufficient evidence of their effectiveness. Here, we aimed to evaluate real-world treatment choice and efficacy of treatments after T-DM1 for HER2-positive metastatic breast cancer. Methods In this multi-centre retrospective cohort study involving 17 hospitals, 325 female HER2-positive metastatic breast cancer patients whose post-T-DM1 treatment began between April 15, 2014 and December 31, 2018 were enrolled. The primary end point was the objective response rate (ORR) of post-T-DM1 treatments. Secondary end points included disease control rate (DCR), progression-free survival (PFS), time to treatment failure (TTF), and overall survival (OS). Results The median number of prior treatments of post-T-DM1 treatment was four. The types of post-T-DM1 treatments included (1) chemotherapy in combination with trastuzumab and pertuzumab (n = 102; 31.4%), (2) chemotherapy concomitant with trastuzumab (n = 78; 24.0%), (3), lapatinib with capecitabine (n = 63; 19.4%), and (4) others (n = 82; 25.2%). ORR was 22.8% [95% confidence interval (CI): 18.1–28.0], DCR = 66.6% (95% CI 60.8–72.0), median PFS = 6.1 months (95% CI 5.3–6.7), median TTF = 5.1 months (95% CI 4.4–5.6), and median OS = 23.7 months (95% CI 20.7–27.4). Conclusion The benefits of treatments after T-DM1 are limited. Further investigation of new treatment strategies beyond T-DM1 is awaited for HER2-positive metastatic breast cancer patients.
  • Takashi Kurosaki; Seiichiro Mitani; Kaoru Tanaka; Shinichiro Suzuki; Hiroaki Kanemura; Koji Haratani; Soichi Fumita; Tsutomu Iwasa; Hidetoshi Hayashi; Takeshi Yoshida; Kazuki Ishikawa; Mutsukazu Kitano; Naoki Otsuki; Yasumasa Nishimura; Katsumi Doi; Kazuhiko Nakagawa
    Anti-cancer drugs 32 (1) 95 - 101 2021/01 
    Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic therapy has not been optimized. This study aimed to evaluate the safety and efficacy of cetuximab-containing chemotherapy after immunotherapy. We retrospectively analyzed patients with recurrent or metastatic SCCHN who underwent cetuximab-containing regimens after progression on immunotherapy. Of the 22 patients who met the inclusion criteria, 21 received paclitaxel and cetuximab, and 1 carboplatin and fluorouracil and cetuximab after immunotherapy. Nine patients achieved a partial response, 10 patients had stable disease as their best response on cetuximab-containing chemotherapy, yielding an overall response rate and disease control rate of 40.9 and 86.4%, respectively. The median progression-free survival was 5.2 months, and the median overall survival was 14.5 months. Ten patients developed grade 3-4 adverse events, including neutropenia (31.8%), acneiform rash (9.1%), anemia (4.5%), hypertransaminasemia (4.5%) and stomatitis (4.5%). The most frequent cetuximab-related toxicities across all grades were skin reactions (77.3%), hypomagnesemia (40.9%), stomatitis (27.3%), paronychia (13.6%) and keratitis (4.5%). There was no treatment-related death. Taken together, cetuximab-containing chemotherapy was effective and feasible even after immunotherapy.
  • 当院におけるアベマシクリブの使用経験
    黒崎 隆; 岩朝 勤; 渡邉 諭美; 酒井 瞳; 橋本 幸彦; 菰池 佳史; 中川 和彦
    日本乳癌学会総会プログラム抄録集 (一社)日本乳癌学会 28回 422 - 422 2020/10
  • Toshinari Yamashita; Norikazu Masuda; Shigehira Saji; Kazuhiro Araki; Yoshinori Ito; Toshimi Takano; Masato Takahashi; Junji Tsurutani; Kei Koizumi; Masahiro Kitada; Yasuyuki Kojima; Yasuaki Sagara; Hiroshi Tada; Tsutomu Iwasa; Takayuki Kadoya; Tsuguo Iwatani; Hiroki Hasegawa; Satoshi Morita; Shinji Ohno
    Trials 21 (1) 503 - 503 2020/06 
    An amendment to this paper has been published and can be accessed via the original article.
  • Toshinari Yamashita; Norikazu Masuda; Shigehira Saji; Kazuhiro Araki; Yoshinori Ito; Toshimi Takano; Masato Takahashi; Junji Tsurutani; Kei Koizumi; Masahiro Kitada; Yasuyuki Kojima; Yasuaki Sagara; Hiroshi Tada; Tsutomu Iwasa; Takayuki Kadoya; Tsuguo Iwatani; Hiroki Hasegawa; Satoshi Morita; Shinji Ohno
    Trials 21 (1) 391 - 391 2020/05 [Refereed]
     
    BACKGROUND: Trastuzumab (Tmab), pertuzumab (Pmab), and taxane has been a standard first-line treatment for recurrent or metastatic human epidermal growth factor (HER2)-positive breast cancer (HER2+ mBC) but has some safety issues due to taxane-induced toxicities. This has led to ongoing efforts to seek less toxic alternatives to taxanes that are equally effective when used in combination with Tmab plus Pmab. This study aims to show the non-inferiority of eribulin, a non-taxane microtubule inhibitor, against taxane, as a partner for dual HER2 blockade. METHODS/DESIGN: This multicenter, randomized, open-label, parallel-group, phase III study will involve a total of 480 Japanese women with HER2+ mBC who meet the following requirements: (1) age 20-70 years; (2) no prior cytotoxic chemotherapy (excluding trastuzumab-emtansine) for mBC; (3) ≥ 6 months after prior neoadjuvant or adjuvant cytotoxic chemotherapy; (4) presence of any radiologically evaluable lesion; (5) left ventricular ejection fraction ≥ 50%; (6) Eastern Cooperative Oncology Group performance status score of 0 or 1; (7) adequate organ function; and (8) life expectancy of at least 6 months. They will be randomized 1:1 to receive eribulin (1.4 mg/m2 on days 1 and 8) or taxane (docetaxel 75 mg/m2 on day 1 or paclitaxel 80 mg/m2 on days 1, 8, and 15) in combination with Tmab (8 mg/kg then 6 mg/kg) plus Pmab (840 mg then 420 mg) on day 1 of each 21-day cycle. The treatment will be continued until disease progression or unmanageable toxicity. The primary endpoint is progression-free survival as per investigator according to RECIST v1.1 criteria. Key secondary endpoints include objective response rate, overall survival, quality of life and safety. Non-inferiority will be tested with two margins of 1.33 and 1.25 in a stepwise manner. If non-inferiority is shown with a margin of 1.25, superiority will then be tested. DISCUSSION: If this study shows the non-inferiority, or even superiority, of Tmab, Pmab, and eribulin against the existing taxane-containing regimen, this new regimen may become a standard first- or second-line treatment option for HER2+ mBC in Japan. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03264547. Registered on 28 June 2017.
  • 岩朝 勤; 黒崎 隆; 鈴木 慎一郎; 田中 薫; 武田 真幸; 中川 和彦
    肺癌 (NPO)日本肺癌学会 60 (2) 164 - 164 0386-9628 2020/04
  • 肺線維症をもつ悪性胸膜中皮腫患者へのニボルマブ使用報告
    岩朝 勤; 黒崎 隆; 鈴木 慎一郎; 田中 薫; 武田 真幸; 中川 和彦
    肺癌 (NPO)日本肺癌学会 60 (2) 164 - 164 0386-9628 2020/04
  • 加藤 了資; 林 秀敏; 米阪 仁雄; 原谷 浩司; 酒井 瞳; 高濱 隆幸; 岩朝 勤; 田中 薫; 吉田 健史; 武田 真幸; 金田 裕靖; 清水 重喜; 坂井 和子; 伊藤 彰彦; 西尾 和人; 中川 和彦
    肺癌 (NPO)日本肺癌学会 59 (6) 575 - 575 0386-9628 2019/11
  • Tsutomu Iwasa; Junji Tsurutani; Satomi Watanabe; Ryoji Kato; Yutaka Mizuno; Yasuyuki Kojima; Tsutomu Takashima; Nobuki Matsunami; Takashi Morimoto; Jun Yamamura; Shoichiro Ohtani; Yuko Tanabe; Tetsuhiro Yoshinami; Toshimi Takano; Yoshifumi Komoike; Kazuhiko Nakagawa
    BMC cancer 19 (1) 962 - 962 2019/10 [Refereed]
     
    BACKGROUND: We previously reported the synergistic effect of S-1 and eribulin in preclinical models. In addition, our phase I study revealed the recommended dose for the phase II study of the combination therapy in advanced breast cancer (ABC) patients pre-treated with anthracycline and taxane. Our current study reports on the efficacy and safety of the combined use of eribulin and S-1 in patients with ABC and poor prognosis. METHODS: Patients with breast cancer who received prior anthracycline- and/or taxane-based therapy were assigned to receive a combination therapy of eribulin (1.4 mg/m2 on days 1 and 8, every 21 days) and S-1 (65 mg/m2, on days 1 to 14, every 21 days) for advanced/metastatic disease. All patients had at least one clinicopathological factor such as being oestrogen receptor negative, Human Epidermal Growth Factor Receptor 2 (HER2) receptor negative, presence of visceral involvement, presence of three or more metastatic sites, or having a disease-free interval shorter than 2 years. The primary endpoint was the independent-reviewer assessed objective response rate (ORR). Secondary endpoints were clinical benefit rate, disease control rate, progression-free survival (PFS), and overall survival (OS). RESULTS: This study enrolled 33 patients. Confirmed ORR was 33.3% (95% CI: 17.3 to 52.8). Median PFS was 7.5 months (95% CI: 4.0 to 14.3). Median OS time was not reached during the current experimental periods. The most common grade 3/4 adverse event was neutropenia (68.8%). CONCLUSIONS: The combination of eribulin and S-1 is safe and effective for treatment in patients with ABC and poor prognosis. TRIAL REGISTRATION: Current Controlled Trials UMIN000015049 , date of registration: September 5th 2014.
  • Takayuki Iwamoto; Naoki Niikura; Rin Ogiya; Hiroyuki Yasojima; Ken-Ichi Watanabe; Chizuko Kanbayashi; Michiko Tsuneizumi; Akira Matsui; Tomomi Fujisawa; Tsutomu Iwasa; Tadahiko Shien; Shigehira Saji; Norikazu Masuda; Hiroji Iwata
    Scientific reports 9 (1) 13343 - 13343 2019/09 
    Our objectives were to determine whether clinic-pathological markers and immune-related gene signatures in breast cancer exhibit any change upon brain metastasis and whether previously reported genes significantly associated with brain metastases and the epithelial-mesenchymal transition (EMT) were reproducible and consistent in our dataset. Sixteen pair-matched samples from primary breast cancers and brain metastases diagnosed were collected from the Japan Clinical Oncology Group Breast Cancer Study Group. Gene expression profiles for immune-, brain metastases-, and EMT-related genes were compared between primary breast cancers and brain metastases. Potential therapeutic target genes of 41 FDA-approved or under-investigation agents for brain metastases were explored. Immune-related signatures exhibited significantly lower gene expression in brain metastases than in primary breast cancers. No significant differences were detected for the majority of genes associated with brain metastases and EMT in the two groups. Among 41 therapeutic target candidates, VEGFA and DNMT3A demonstrated significantly higher gene expression in brain metastases. We found that distinct patterns of gene expression exist between primary breast cancers and brain metastases. Further studies are needed to explore whether these distinct expression profiles derive from or underlie disease status and compare these features between metastases to the brain and other sites.
  • Sakai K; Takeda M; Shimizu S; Takahama T; Yoshida T; Watanabe S; Iwasa T; Yonesaka K; Suzuki S; Hayashi H; Kawakami H; Nonagase Y; Tanaka K; Tsurutani J; Saigoh K; Ito A; Mitsudomi T; Nakagawa K; Nishio K
    Scientific reports NATURE PUBLISHING GROUP 9 (1) 11340  2045-2322 2019/08 [Refereed]
     
    Medical oncologists are challenged to personalize medicine with scientific evidence, drug approvals, and treatment guidelines based on sequencing of clinical samples using next generation sequencer (NGS). Knowledge-based curation systems have the potential to help address this challenge. We report here the results of examining the level of evidence regarding treatment approval and clinical trials between recommendations made by Watson for Genomics (WfG), QIAGEN Clinical Insight Interpret (QCII), and Oncomine knowledge-based reporter (OKR). The tumor samples obtained from the solid cancer patients between May to June 2018 at Kindai University Hospital. The formalin-fixed paraffin-embedded tumor samples (n = 31) were sequenced using Oncomine Comprehensive Assay v3. Variants including copy number alteration and gene fusions identified by the Ion reporter software were used commonly on three curation systems. Curation process of data were provided for 25 solid cancers using three curation systems independently. Concordance and distribution of curated evidence levels of variants were analyzed. As a result of sequencing analysis, nonsynonymous mutation (n = 58), gene fusion (n = 2) or copy number variants (n = 12) were detected in 25 cases, and subsequently subjected to knowledge-based curation systems (WfG, OKR, and QCII). The number of curated information in any systems was 51/72 variants. Concordance of evidence levels was 65.3% between WfG and OKR, 56.9% between WfG and QCII, and 66.7% between OKR and QCII. WfG provided great number of clinical trials for the variants. The annotation of resistance information was also observed. Larger differences were observed in clinical trial matching which could be due to differences in the filtering process among three curation systems. This study demonstrates knowledge-based curation systems (WfG, OKR, and QCII) could be helpful tool for solid cancer treatment decision making. Difference in non-concordant evidence levels was observed between three curation systems, especially in the information of clinical trials. This point will be improved by standardized filtering procedure and enriched database of clinical trials in Japan.
  • 乳がん原発・脳転移巣の遺伝子発現から探る脳転移機序の検討
    岩本 高行; 新倉 直樹; 扇谷 りん; 八十島 宏行; 渡邊 健一; 神林 智寿子; 常泉 道子; 松井 哲; 藤澤 知巳; 岩朝 勤; 枝園 忠彦; 佐治 重衡; 増田 慎三; 岩田 広治; JCOG(日本臨床腫瘍研究グループ)
    日本乳癌学会総会プログラム抄録集 (一社)日本乳癌学会 27回 464 - 464 2019/07
  • Watanabe S; Otani T; Iwasa T; Takahama T; Takeda M; Sakai K; Nishio K; Ito A; Nakagawa K
    Clinical breast cancer 19 (5) e589-e592  1526-8209 2019/06 [Refereed]
  • Sakai Hitomi; Tsurutani Junji; Iwasa Tsutomu; Komoike Yoshifumi; Sakai Kazuko; Nishio Kazuto; Nakagawa Kazuhiko
    Breast Cancer シュプリンガー・ジャパン(株) 25 (5) 605 - 613 1340-6868 2018/09 
    循環腫瘍DNA(ctDNA)のゲノム解析とその他のヒト上皮成長因子受容体2(HER2)陽性進行性乳癌(ABC)患者の臨床病理学的特徴を合わせて、trastuzumab emtasine(T-DM1)に対する初期耐性を予測した。T-DM1による治療を受けたHER2陽性ABC患者34例(年齢中央値62歳)を対象とした。患者の臨床病理学的特徴とT-DM1に対する初期耐性との相関関係を調べ、T-DM1を投与する前の患者16例から採取した血漿ctDNA検体を用いてHER2遺伝子コピー数とPIK3CA遺伝子突然変異を解析した。初回有効性解析の時点で疾患進行がみられた患者は9例で、これらの患者はT-DM1に対する初期耐性を有するとみなした。2群の間でT-DM1に対する初期耐性率の有意差は認められなかった。ctDNAを解析した16例のうち、4例がT-DM1に対する初期耐性を示した。これらの4例は、ctDNAにおけるHER2遺伝子増幅が陰性で、免疫組織化学検査ではエストロゲン受容体陽性および/またはプロゲステロン受容体陽性であった。
  • Furuse J; Kurata T; Okano N; Fujisaka Y; Naruge D; Shimizu T; Kitamura H; Iwasa T; Nagashima F; Nakagawa K
    Cancer chemotherapy and pharmacology 82 (3) 511 - 519 0344-5704 2018/09 [Refereed]
     
    PURPOSE: Patients with RAS-positive tumors respond poorly to chemotherapies and have a few treatment options. Salirasib is an oral RAS inhibitor that competitively blocks the membrane association of RAS proteins. The aim of this phase I multiple-ascending-dose clinical trial was to investigate the safety and pharmacokinetics of Salirasib in Japanese patients with relapsed/refractory solid tumors and to explore its efficacy. METHODS: Salirasib was started at a dose of 100-mg twice-daily and escalated to a maximum of 1000-mg twice-daily from days 1 to 21 of a 28-day regimen. The pharmacokinetics was evaluated on days 1 and 21. Dose-limiting toxicity (DLT) and adverse events (AEs) were monitored throughout the trial. Patients with stable disease or better repeated the dosing regimen. RESULTS: A total of 21 patients received Salirasib. Among 14 patients tested, 4 had KRAS mutations. Cmax and AUCinf were maximal at 800 mg. No maximum tolerable dose was discerned, as no DLT was observed in any dosing group. The most frequently observed AEs were gastrointestinal disturbances, including diarrhea, abdominal pain, and nausea. No AEs led to discontinuation. All patients completed the first regimen and 11 patients repeated the regimen (median: 2 cycles; range: 1-13). Patients with KRAS mutations showed median progression-free survival of 227 days (range: 79-373). CONCLUSION: Salirasib was safe and well tolerated in Japanese patients, and 800-mg twice-daily is recommended for phase II trials. Although the number of participants with KRAS mutations was limited, the remarkably long progression-free period warrants further investigation. CLINICAL TRIAL REGISTRATION: JAPIC Clinical Trials Information; JapicCTI-121751.
  • Nonagase Y; Takeda M; Tanaka K; Hayashi H; Iwasa T; Nakagawa K
    Oncotarget 9 (50) 29532 - 29535 2018/06 [Refereed]
     
    © Nonagase et al. Malignant tumors can induce a hypercoagulable state known as Trousseau syndrome that increases the risk for venous thromboembolism including disabling cerebral infarction. Anticoagulant therapy without anticancer treatment is not effective for amelioration of this coagulation abnormality. Most patients with lung cancer positive for activating mutations of the epidermal growth factor receptor (EGFR) are sensitive to EGFR tyrosine kinase inhibitors (TKIs), but the efficacy and safety of EGFR-TKIs in such patients with a poor performance status (PS) due to Trousseau syndrome has been unclear. We here describe a patient with EGFR mutation-positive lung cancer who developed disabling cerebral infarction due to Trousseau syndrome. Administration of the EGFR-TKI gefitinib and anticoagulant therapy resulted in a partial tumor response and recovery from both the coagulation abnormality and the severe neurological symptoms. After the development of resistance to gefitinib, the EGFR-TKI osimertinib was safely administered until disease progression without recurrence of the coagulation abnormality. This case suggests that gefitinib followed by osimertinib may be a safe and effective treatment option for patients with EGFR mutation-positive lung cancer who experience disabling cerebral infarction due to Trousseau syndrome.
  • 進行性/再発性乳癌に対するeribulin/S-1併用療法の第II相試験(Phase II trial of Eribulin/S-1 combination therapy for advanced/recurrent breast cancer)
    鶴谷 純司; 岩朝 勤; 水野 豊; 小島 康幸; 高島 勉; 松並 展輝; 森本 卓; 山村 順; 大谷 彰一郎; 田辺 裕子; 渡邉 諭美; 加藤 了資; 高野 利美; 菰池 佳史; 中川 和彦
    日本乳癌学会総会プログラム抄録集 (一社)日本乳癌学会 26回 334 - 334 2018/05
  • 乳癌化学療法による外見変化に対する医師の認識と介入の実態調査
    酒井 瞳; 岩朝 勤; 鶴谷 純司; 菰池 佳史
    日本乳癌学会総会プログラム抄録集 (一社)日本乳癌学会 26回 363 - 363 2018/05
  • 当院における高齢者への化学療法施行の現状に関して
    岩朝 勤; 鶴谷 純司; 酒井 瞳; 渡邊 諭美; 新崎 亘; 安積 達也; 橋本 幸彦; 菰池 佳史
    日本乳癌学会総会プログラム抄録集 (一社)日本乳癌学会 26回 532 - 532 2018/05
  • 初発骨転移症例の予後規定因子の検討
    菰池 佳史; 東 千尋; 田中 裕美子; 濱田 未佳; 新崎 亘; 橋本 幸彦; 北條 敏也; 乾 浩己; 鶴谷 純司; 岩朝 勤; 酒井 瞳; 大和 宗久; 金泉 博文; 山村 順
    日本乳癌学会総会プログラム抄録集 (一社)日本乳癌学会 26回 636 - 636 2018/05
  • Hitomi Sakai; Junji Tsurutani; Tsutomu Iwasa; Yoshifumi Komoike; Kazuko Sakai; Kazuto Nishio; Kazuhiko Nakagawa
    Breast Cancer Springer Tokyo 25 (5) 1 - 9 1880-4233 2018/04 [Refereed]
     
    Background: Trastuzumab emtansine (T-DM1) is approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC), and has high efficacy. However, some patients exhibit primary resistance to T-DM1, and thus methods that can predict resistance in clinical practice are needed. Genomic analysis of circulating tumor DNA (ctDNA) in plasma is a non-invasive and reproducible method. This study aimed to predict primary resistance to T-DM1 by combining genomic analysis of ctDNA and other clinicopathological features of patients with HER2-positive ABC. Methods: The study population comprised 34 patients with HER2-positive ABC who had been treated with T-DM1. Correlations between clinicopathological characteristics of patients and primary resistance to T-DM1 were examined, and HER2 gene copy number and PIK3CA gene mutations were analyzed using plasma ctDNA samples obtained from 16 patients before T-DM1 administration. Results: Among the 34 patients, nine (26.5%) had progressive disease at the first efficacy analysis these patients were considered to have primary resistance to T-DM1. No significant difference was found in the rate of primary resistance to T-DM1 between groups. Among 16 patients whose ctDNA was analyzed, four showed primary resistance to T-DM1. These four patients showed negative HER2 gene amplification in ctDNA and were ER-positive and/or PR-positive by immunohistochemistry. Conclusions: HER2 gene amplification in ctDNA and ER and PR status may predict primary resistance to T-DM1. A liquid biopsy before the initiation of T-DM1 treatment could be a non-invasive way to predict whether a patient would exhibit primary resistance to T-DM1.
  • Nagashima Y; Yoshino S; Yamamoto S; Maeda N; Azumi T; Komoike Y; Okuno K; Iwasa T; Tsurutani J; Nakagawa K; Masaaki O; Hiroaki N
    Molecular and clinical oncology 7 (3) 359 - 366 2049-9450 2017/09 [Refereed]
     
    Anthracycline-based chemotherapies for breast cancer are known to adversely affect patients' quality of life (QOL) and immune function. For that reason, adjuvants that improve those impairments are required. A randomized double-blind study was conducted to evaluate the effectiveness of Lentinula edodes mycelia extract (LEM), which is an oral biological response modifier (BRM) medicine for cancer patients as such an adjuvant. A total of 47 breast cancer patients who were scheduled to receive postoperative adjuvant anthracycline-based chemotherapy, i.e., 5-fluorouracil (5-FU) + cyclophosphamide + epirubicin (FEC regimen), 5-FU + cyclophosphamide + doxorubicin/pirarubicin (FAC regimen), cyclophosphamide + doxorubicin/pirarubicin (AC regimen) and cyclophosphamide + epirubicin (EC regimen), were entered in the study. The patients were randomly divided into either an LEM or a placebo tablet group; the tablets were orally ingested daily over 2 courses of each therapy. In the placebo group, the total scores for QOL were lower on day 8 of the second course of chemotherapy compared with the baseline scores, whereas in the LEM group the scores had not decreased. In the placebo group, the QOL functional well-being score was lower on day 8 after both the first and second courses of chemotherapy compared with the baseline score, but it had not decreased in the LEM group. Evaluation of immunological parameters indicated that an increase in the proportion of regulatory T cells to peripheral blood CD4+ cells tended to be inhibited in the LEM group compared with the placebo group. Oral LEM that was coadministered with anthracycline-based chemotherapies was useful for maintaining patients' QOL and immune function. Thus, LEM appears to be a useful oral adjuvant for patients receiving anthracycline-based chemotherapy.
  • Toshio Shimizu; Kimio Yonesaka; Hidetoshi Hayashi; Tsutomu Iwasa; Koji Haratani; Hironori Yamada; Shoichi Ohwada; Emi Kamiyama; Kazuhiko Nakagawa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY SPRINGER 79 (3) 489 - 495 0344-5704 2017/03 [Refereed]
     
    This phase 1 study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287) Process 2, a new formulation of fully human anti-HER3 monoclonal antibody in combination with erlotinib, an epidermal growth factor receptortyrosine kinase inhibitor (EGFR-TKI) in prior chemotherapy treated Japanese patients with advanced non-small cell lung cancer (NSCLC). Patients received intravenous patritumab Process 2 formulation at 9 mg/kg every 3 weeks after initiation of 18 mg/kg loading dose combined with continuous daily dose of erlotinib (150 mg QD) until any of the withdrawal criteria are met. Adverse events (AEs) were assessed using CTCAE v4.0 and tumor response was assessed using RECIST v1.1. Full pharmacokinetic sampling and serum biomarker analyses were mainly performed during cycle 1 and 2. Total of six EGFR-mutant NSCLC patients including one EGFR-TKI na < ve patient received patritumab Process 2 formulation combined with erlotinib. No dose-limiting toxicities were observed. The most frequent AEs were gastrointestinal or skin toxicities, which were generally mild and manageable. One patient discontinued from study due to reversible grade 3 interstitial lung disease. The mean area under the curve (AUC) value was 2640 mu g/day/mL; the Cmax value was 434 mu g/mL, respectively. The median progression-free survival (95% confidence interval) was 220.0 (100.0-363.0) days. HER3 ligand heregulin was detected in serum from only a patient that maintained most durable stable disease. Patritumab Process 2 formulation in combination with erlotinib was well tolerated compatible with favorable PK profile in Japanese patients with advanced NSCLC.
  • Sakai H; Hayashi H; Iwasa T; Hasegawa Y; Takeda M; Nakagawa K
    ESMO open 2 (Suppl 1) e000104  2017 [Refereed]
  • Rin Ogiya; Naoki Niikura; Nobue Kumaki; Hiroyuki Yasojima; Tsutomu Iwasa; Chizuko Kanbayashi; Risa Oshitanai; Michiko Tsuneizumi; Ken-ichi Watanabe; Akira Matsui; Tomomi Fujisawa; Shigehira Saji; Norikazu Masuda; Yutaka Tokuda; Hiroji Iwata
    Oncotarget Impact Journals LLC 8 (61) 103671 - 103681 1949-2553 2017 [Refereed]
     
    Background: Immune checkpoint inhibitors are reported to be effective in patients with brain metastases. However, detailed characteristics of the brain metastasis immune microenvironment remain unexplored. Results: The median tumor-infiltrating lymphocyte (TIL) category in brain metastases was 5% (1-70%). In 46 pair-matched samples, the percentages of TILs were significantly higher in primary breast tumors than in brain metastases (paired t-test, P < 0.01). The numbers of CD4/CD8/Foxp3-positive cells were significantly higher in primary breast tumors than in brain metastases (paired t-test, P < 0.05 for all antibodies). In patients with triple-negative breast cancer specifically, low TIL numbers were associated with significantly shorter overall survival compared to high TIL numbers (log-rank test, P = 0.04). Materials and Methods: We retrospectively identified 107 patients with breast cancer and brain metastases who had undergone surgery between 2001 and 2012 at 8 institutions, and collected 191 samples including brain metastases alone and primary tumors with pair-matched brain metastasis samples. Hematoxylin and eosin-stained slides were evaluated for TILs and categorized according to the extent of staining. Immunohistochemistry for CD4, CD8, Foxp3, PD-L1, PD-L2, and HLA class I was also performed. Conclusions: There are significantly fewer TILs in brain metastases than in primary breast tumors.
  • Satomi Watanabe; Masayuki Takeda; Takayuki Takahama; Tsutomu Iwasa; Junji Tsurutani; Junko Tanizaki; Toshio Shimizu; Kazuko Sakai; Yoshitaka Wada; Noritaka Isogai; Kazuto Nishio; Kazuhiko Nakagawa
    INVESTIGATIONAL NEW DRUGS SPRINGER 34 (3) 394 - 396 0167-6997 2016/06 [Refereed]
     
    Extramammary Paget's disease is a malignant intraepithelial carcinoma, which constitutes less than 1 % of all vulvar malignancies. Surgical resection is the first treatment of choice and standard chemotherapy has not been established for advanced or recurrent disease. Experimental and clinical studies have identified human epidermal growth receptor 2 as a potential therapeutic target. A 63-year-old male was referred for recurrent extramammary Paget's disease after surgery. Human epidermal growth receptor 2 was shown to be overexpressed and amplified by immunohistochemical analysis and fluorescence in situ hybridization analysis, respectively. After two cycles of trastuzumab monotherapy, all lymph node metastases decreased in size. However, he experienced recurrence in the lymph nodes during the seven courses of trastuzumab. As a subsequent treatment, trastuzumab was administered in combination with docetaxel and pertuzumab; clinical response was sustained for 12 months without significant adverse events.
  • Toshio Shimizu; Takashi Seto; Fumihiko Hirai; Mitsuhiro Takenoyama; Kaname Nosaki; Junji Tsurutani; Hiroyasu Kaneda; Tsutomu Iwasa; Hisato Kawakami; Kazuo Noguchi; Takashi Shimamoto; Kazuhiko Nakagawa
    INVESTIGATIONAL NEW DRUGS SPRINGER 34 (3) 347 - 354 0167-6997 2016/06 [Refereed]
     
    Background This phase I study evaluated the safety and tolerability, pharmacokinetics and pharmacodynamics, immunogenicity, and antitumor activity of pembrolizumab in Japanese patients with advanced solid tumors. Methods Following an initial dose and a 28-day rest (cycle 1), pembrolizumab was administered as an intravenous infusion at escalating doses (2 or 10 mg/kg) every 2 weeks (Q2W) until disease progression or unacceptable toxicity. Adverse events (AEs) were assessed using CTCAE v4.0, and tumor response was assessed using both RECIST v1.1 and immune-related response criteria (irRC). Full pharmacokinetic sampling was performed during cycle 1. Results Three patients received pembrolizumab at 2.0 mg/kg and seven at 10 mg/kg. No dose-limiting toxicities were observed during cycle 1. Eighty percent of patients experienced drug-related AEs (mostly grade 1 or 2); the most common drug-related AEs were nausea, malaise, pyrexia, and aspartate aminotransferase/alanine transaminase (AST/ALT) elevations (n = 2 each). No drug-related grade 4 or 5 AEs occurred. Immune-related AEs comprised grade 3 ALT elevation (n = 1), grade 3 AST elevation (n = 1), grade 1 pneumonitis (n = 1), and grade 1 thyroid-stimulating hormone elevation (n = 1). The safety and pharmacokinetic profiles of Japanese patients were similar to those previously reported for Caucasian patients. A partial tumor response was observed in one patient with non-small-cell lung cancer (NSCLC) and in one patient with melanoma. Conclusions Pembrolizumab at both 2 and 10 mg/kg Q2W was well tolerated in Japanese patients with advanced solid tumors and showed encouraging anti-tumor activity against melanoma and NSCLC.
  • Shimizu Toshio; Nishio Kazuto; Sakai Kazuko; Hayashi Hidetoshi; Okamoto Kunio; Takeda Masayuki; Iwasa Tsutomu; Tanaka Kaoru; Aoyama Koji; Morishita Maiko; Nakagawa Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY 34 (15) 0732-183X 2016/05 [Refereed]
  • Shimizu T; Fukuoka K; Takeda M; Iwasa T; Yoshida T; Horobin J; Keegan M; Vaickus L; Chavan A; Padval M; Nakagawa K
    Cancer Chemother Pharmacol. 77 (5) 997 - 1003 2016/05 [Refereed]
     
    PURPOSE: VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich tyrosine kinase-2. This phase 1 study evaluated the safety and tolerability, pharmacokinetics, and clinical activity of VS-6063 in Japanese subjects with advanced solid tumor malignancies in a first-in-Asian study setting. METHODS: VS-6063 was administered orally twice daily (b.i.d.) in 21-day cycles to cohorts of three subjects each with a standard 3 + 3 dose-escalation design until disease progression or unacceptable toxicity. Blood samples for pharmacokinetics were collected on Day 1 and 15. The assessments were performed using CTCAE v4.0 for adverse events (AEs), and the Response Evaluation Criteria In Solid Tumors, version v1.1 (RECIST v1.1) for tumor response. RESULTS: Nine patients were treated across three dose levels (200-600 mg BID). No dose-limiting toxicities were observed at any dose level. Most frequent treatment-related AEs were Grade 1/2 unconjugated hyperbilirubinemia, fatigue, decreased appetite, and diarrhea. Only one subject in the 200 mg BID cohort experienced reversible and transient Grade 3 unconjugated hyperbilirubinemia. PK analyses confirmed that the exposure at the recommended Phase 2 dose (RP2D) of 400 mg BID was comparable with exposures previously reported in non-Japanese subjects. Durable stable disease of approximately 24 weeks was confirmed in two subjects (malignant mesothelioma and rectal cancer). CONCLUSIONS: VS-6063 was well tolerated at all dose levels investigated in this first-in-Asian study. These data support the administration of VS-6063 to Japanese subjects at the RP2D in clinical trials involving solid tumor malignancies.
  • Yoshikane Nonagase; Kunio Okamoto; Tsutomu Iwasa; Takeshi Yoshida; Kaoru Tanaka; Masayuki Takeda; Hiroyasu Kaneda; Toshio Shimizu; Junji Tsurutani; Kazuhiko Nakagawa
    ANTI-CANCER DRUGS LIPPINCOTT WILLIAMS & WILKINS 27 (3) 251 - 253 0959-4973 2016/03 [Refereed]
     
    Both afatinib and erlotinib are tyrosine kinase inhibitors that inhibit aberrant epidermal growth factor receptor (EGFR) signals in non-small-cell lung cancer (NSCLC). Afatinib is an irreversible inhibitor directed against EGFR, ErbB-2, and ErbB-4, whereas erlotinib is a reversible inhibitor directed against EGFR only. Although afatinib has been shown to be effective in the treatment for erlotinib-refractory and/or gefitinib-refractory central nervous system metastases from NSCLC, little is known about the efficacy of erlotinib for afatinib-refractory central nervous system metastases. In the present report we describe a case of EGFR mutation-positive NSCLC in which brain metastases developed during first-line afatinib treatment. Whole-brain radiation therapy and substitution of erlotinib for afatinib led to successful shrinkage of the brain metastases. Our report highlights the potential benefit of erlotinib for the management of brain metastases refractory over afatinib in patients with NSCLC.
  • Takeda M; Sakai K; Terashima M; Kaneda H; Hayashi H; Tanaka K; Okamoto K; Takahama T; Yoshida T; Iwasa T; Shimizu T; Nonagase Y; Kudo K; Tomida S; Mitsudomi T; Saigo K; Ito A; Nakagawa K; Nishio K
    Ann Oncol 26 (12) 2477 - 2482 0923-7534 2015/12 [Refereed]
     
    Background: The clinical implementation of genomic profiling for lung cancer with high-throughput, multiplex tests is warranted to allow prioritization of appropriate therapies for individual patients. We have now applied such testing to detect actionable mutations that may inform treatment recommendations in lung cancer. Patients and methods: We prospectively applied amplicon sequencing panels that cover both mutational hotspots in 22 genes related to lung and colon tumorigenesis as well as 72 major variants of ALK, RET, ROS1, and NTRK1 fusion transcripts. We then determined the proportion of patients who received genotype-directed therapy and their overall survival (OS). Results: Tumor specimens from 110 patients with lung cancer recruited between July 2013 and March 2015 were analyzed. The most common genetic alterations were TP53 mutations in 42 patients, followed by EGFR mutations in 25, STK11 mutations in 12, and KRAS mutations in 10. Potentially actionable mutations were identified in 44 patients including 50% of those with adenocarcinoma and 14% of those with squamous cell carcinoma. The OS of patients with advanced or recurrent cancer who had an actionable mutation and received targeted therapy (median OS not achieved) was significantly longer than that of those with no mutation (18.1 months, P = 0.041) or of those with a mutation not so treated (6.1 months, P = 0.0027). Conclusions: Multiplex genomic testing was performed on formalin-fixed, paraffin-embedded tumor specimens with a success rate of ≥95%. Such testing can assist physicians in matching patients with approved or experimental targeted treatments. Clinical trial registration: The University Medical Hospital Information Network (UMIN) Clinical Trials Registry under the identifier UMIN000014782.
  • Kimio Yonesaka; Keita Kudo; Satomi Nishida; Takayuki Takahama; Tsutomu Iwasa; Takeshi Yoshida; Kaoru Tanaka; Masayuki Takeda; Hiroyasu Kaneda; Isamu Okamoto; Kazuto Nishio; Kazuhiko Nakagawa
    ONCOTARGET IMPACT JOURNALS LLC 6 (32) 33602 - 33611 1949-2553 2015/10 [Refereed]
     
    Afatinib is a second generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) characterized as an irreversible pan-human EGFR (HER) family inhibitor. Afatinib remains effective for a subpopulation of patients with non-small cell lung cancer (NSCLC) with acquired resistance to first generation EGFF-TKIs such as erlotinib. Heregulin activates HER3 in an autocrine fashion and causes erlotinib resistance in NSCLC. Here we examine whether afatinib is effective against heregulin-overexpressing NSCLCs harboring EGFR activating mutations. Afatinib but not erlotinib decreased EGFR mutant NSCLC PC9HRG cell proliferation in vitro and in mouse xenografts. Afatinib inhibited phosphorylation of the cell signaling pathway proteins HER3, EGFR, HER2, and HER4, likely by prevention of trans-phosphorylation as HER3 kinase activity is inadequate for auto-phosphorylation. Afatinib, unlike erlotinib, inhibited AKT activation, resulting in elevated apoptosis in PC9HRG cells. Clinically, a subpopulation of 33 patients with EGFR mutations and NSCLC who had received first generation EGFR-TKIs exhibited elevated plasma heregulin levels compared to healthy volunteers; one of these achieved a response with afatinib therapy despite having previously developed erlotinib resistance. Afatinib can overcome heregulin-mediated resistance to erlotinib in EGFR mutant NSCLC. Further studies are necessary to determine whether heregulin can predict afatinib efficacy after development offirst generation EGFR-TKI resistance.
  • Takeda Masayuki; Sakai Kazuko; Terashima Masato; Kaneda Hiroyasu; Hayashi Hidetoshi; Tanaka Kaoru; Iwasa Tsutomu; Yoshida Takeshi; Takahama Takayuki; Nishio Kazuto; Nakagawa Kazuhiko
    JOURNAL OF THORACIC ONCOLOGY 10 (9) S700 - S701 1556-0864 2015/09 [Refereed]
  • Junji Tsurutani; Katsumasa Kuroi; Tsutomu Iwasa; Masaki Miyazaki; Shinichi Nishina; Chihiro Makimura; Junko Tanizaki; Kunio Okamoto; Toshinari Yamashita; Tomoyuki Aruga; Takashi Shigekawa; Yoshifumi Komoike; Toshiaki Saeki; Kazuhiko Nakagawa
    CANCER SCIENCE WILEY-BLACKWELL 106 (6) 734 - 739 1347-9032 2015/06 [Refereed]
     
    We conducted a phase I study of a weekly nab-paclitaxel and S-1 combination therapy in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer. The primary objective was to estimate the maximum tolerated and recommended doses. Each treatment was repeated every 21days. Levels 1, 2a, 2b, and 3 were set depending on the S-1 dose (65 or 80mg/m(2)) and nab-paclitaxel infusion schedule (days 1 and 8 or days 1, 8, and 15). Fifteen patients were enrolled. Dose-limiting toxicity was observed in one patient at Level 3 (100mg/m(2)nab-paclitaxel on days 1, 8, and 15 with 80mg/m(2) S-1 daily for 14days, followed by 7days of rest). Although the maximum tolerated dose was not reached, the recommended dose was determined to be Level 3. Neutropenia was the most frequent grade 3-4 treatment-related adverse event. For patients with measurable lesions, the response rate was 50.0% and the median time to treatment failure and median progression-free survival was 13.2 and 21.0months, respectively. The present results show the feasibility and potential for long-term administration of this combination therapy.
  • Sakiyama T; Tsurutani J; Iwasa T; Kawakami H; Nonagase Y; Yoshida T; Tanaka K; Fujisaka Y; Kurata T; Komoike Y; Nishio K; Nakagawa K
    Br J Cancer. 112 (5) 819 - 824 0007-0920 2015/03 [Refereed]
     
    Background: We evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, recommended dose for phase II (P2RD), and preliminary anticancer activity of a combination eribulin and S-1 therapeutic in metastatic breast cancer patients pretreated with anthracycline and taxane.Method:Patients aged 20-74 years were recruited. In level 1, patients received S-1 (65 mg m-2) from day 1 to 14, and eribulin (1.1 mg m-2) on day 1 and 8 in a 21-day cycle. In level 2, eribulin was increased to 1.4 mg m-2. In level 3, S-1 was increased to 80 mg m-2.Results:Twelve patients were enrolled into three cohorts. Planned dose escalation was completed, with one case exhibiting dose-limiting toxicity (grade 3 hypokalaemia) at level 3, without reaching the MTD. The P2RD was determined to be level 2 (eribulin 1.4 mg m-2 and S-1 65 mg m-2). The most common grade 3 or 4 toxicity was neutropenia (83.3%), followed by febrile neutropenia (25.0%). Five of eleven patients (41.7%) with measurable disease had a partial response. Pharmacokinetics were characterised by dose-dependent elimination and nonlinear exposure.Conclusion:Dose level 3 was not tolerated owing to febrile neutropenia development. Thus, intermediate dose level 2 was recommended for further evaluation. Preliminary antitumour activity warrants further investigation in this setting.
  • Tsutomu Iwasa; Tsutomu Sakiyama; Junji Tsurutani; Kaoru Tanaka; Takeshi Yoshida; Yoshikane Nonagase; Yasuhito Fujisaka; Takayasu Kurata; Yoshifumi Komoike; Kazuhiko Nakagawa
    ANNALS OF ONCOLOGY OXFORD UNIV PRESS 25 0923-7534 2014/10 [Refereed]
  • Hiroyasu Kaneda; Masayuki Takeda; Kaoru Tanaka; Takeshi Yoshida; Tsutomu Iwasa; Kunio Okamoto; Hisato Kawakami; Takayuki Takahama; Toshio Shimizu; Kazuhiko Nakagawa
    ANNALS OF ONCOLOGY OXFORD UNIV PRESS 25 0923-7534 2014/10 [Refereed]
  • Hiromichi Matsuoka; Junji Tsurutani; Junko Tanizaki; Tsutomu Iwasa; Yoshifumi Komoike; Atsuko Koyama; Kazuhiko Nakagawa
    BMC Research Notes 6 (1) 541  1756-0500 2013/12 [Refereed]
     
    Background: Eribulin is a recently approved new therapeutic option for patients with metastatic breast cancer. According to several reports, eribulin has limited ability to cross the blood brain barrier. Recently, capecitabine and eribulin have been recognized as drugs with similar application for patients with advanced breast cancer. Although there have been several case reports describing the efficacy of capecitabine against brain metastases, no report of eribulin demonstrating efficacy for brain metastases exists today. Case presentation. We describe a case of a 57-year-old Japanese woman who was diagnosed with breast cancer stage IV metastasized to multiple organs including liver and lung. After she received 3 regimens, she showed evidence of brain metastases, and whole brain radiation therapy was performed. Lapatinib and capecitabine was then administered as fourth-line chemotherapy, but the patient was hospitalized due to the exacerbation of interstitial pneumonitis and progression of brain and liver metastases. To control the systemic disease, eribulin was commenced as fifth-line chemotherapy. One month later, a significant response of brain metastases had been achieved, and this response has persisted for the last 4 months. We now describe a remarkable antitumor effect of eribulin against brain metastases from breast cancer. This case is the first report which indicates potential treatment of brain metastases using this medication. Conclusion: This report suggests that eribulin treatment may be beneficial for breast cancer patients with brain metastases progressing after whole brain radiation therapy. However, further clinical studies are warranted to determine the clinical effect of eribulin in brain metastases. © 2013 Matsuoka et al. licensee BioMed Central Ltd.
  • Regression of brain metastases from breast cancer with eribulin: a case report.
    Matsuoka H; Tsurutani J; Tanizaki J; Iwasa T; Komoike Y; Koyama A; Nakagawa K
    BMC Res Notes. 65 412  2013 [Refereed]
  • Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
    Br J Cancer. 103 (1) 36 - 42 2010 [Refereed]
  • Tsutomu Iwasa; Isamu Okamoto; Minoru Suzuki; Erina Hatashita; Yuki Yamada; Masahiro Fukuoka; Koji Ono; Kazuhiko Nakagawa
    CLINICAL CANCER RESEARCH AMER ASSOC CANCER RESEARCH 15 (16) 5117 - 5125 1078-0432 2009/08 [Refereed]
     
    Purpose: Therapeutic strategies that target the insulin-like growth factor I receptor (IGF-1R) hold promise for a wide variety of cancers. We have now investigated the effect of CP-751,871, a fully human monoclonal antibody specific for IGF-IR, on the sensitivity of human non-small cell lung cancer (NSCLC) cell lines to radiation. Experimental Design: The radiosensitizing effect of CP-751,871 was evaluated on the basis of cell death, clonogenic survival, and progression of tumor xenografts. Radiation-induced damage was evaluated by immunofluorescence analysis of the histone gamma-H2AX and Rad51. Results: A clonogenic survival assay revealed that CP-751,871 increased the sensitivity of NSCLC cells to radiation in vitro. CP-751,871 inhibited radiation-induced IGF-IR signaling, and potentiated the radiation-induced increases both in the number of apoptotic cells and in the activity of caspase-3. Immunofluorescence analysis of the histone gamma-H2AX and Rad51 also showed that CP-751,871 inhibited the repair of radiation-induced DNA double-strand breaks. Finally, combination therapy with CP-751,871 and radiation delayed the growth of NSCLC tumor xenografts in nude mice to a greater extent than did either treatment modality alone. Conclusions: These results show that CP-751,871 sensitizes NSCLC cells to radiation both in vitro and in vivo, and that this effect of CP-751,871 is likely attributable to the inhibition of DNA repair and enhancement of apoptosis that result from attenuation of IGF-IR signaling. Combined treatment with CP-751,871 and radiation thus warrants further investigation in clinical trials as a potential anticancer strategy. (Clin Cancer Res 2009;15(16):5117-25)
  • Takeshi Yoshida; Isamu Okamoto; Tsutomu Iwasa; Masahiro Fukuoka; Kazuhiko Nakagawa
    FEBS LETTERS ELSEVIER SCIENCE BV 582 (30) 4125 - 4130 0014-5793 2008/12 [Refereed]
     
    Cisplatin is a key agent in combination chemotherapy for various types of solid tumor. We now show that cisplatin activates signaling by the epidermal growth factor receptor (EGFR) by inducing cleavage of heparin-binding epidermal growth factor-like growth factor (HB-EGF). Matuzumab, a monoclonal antibody to EGFR, inhibited cisplatin-induced EGFR signaling, likely through competition with the soluble form of HB-EGF for binding to EGFR. Matuzumab enhanced the antitumor effect of cisplatin in nude mice harboring human non-small cell lung cancer xenografts. Our findings shed light on the mechanism by which monoclonal antibodies to EGFR might augment the efficacy of cisplatin. Crown Copyright (c) 2008 Published by Elsevier B. V. on behalf of the Federation of European Biochemical Societies. All rights reserved.
  • Tsutomu Iwasa; Isamu Okamoto; Minoru Suzuki; Takahito Nakahara; Kentaro Yamanaka; Erina Hatashita; Yuki Yamada; Masahiro Fukuoka; Koji Ono; Kazuhiko Nakagawa
    CLINICAL CANCER RESEARCH AMER ASSOC CANCER RESEARCH 14 (20) 6496 - 6504 1078-0432 2008/10 [Refereed]
     
    Purpose: Survivin, a member of the inhibitor of apoptosis protein family, is an attractive target for cancer therapy. We have now investigated the effect of YM155, a small-molecule inhibitor of survivin expression, on the sensitivity of human non-small cell lung cancer (NSCLC) cell lines to gamma-radiation. Experimental Design: The radiosensitizing effect of YM155 was evaluated on the basis of cell death, clonogenic survival, and progression of tumor xenografts. Radiation-induced DNA damage was evaluated on the basis of histone H2AX phosphorylation and foci formation. Results: YM155 induced down-regulation of survivin expression in NSCLC cells in a concentration-and time-dependent manner. A clonogenic survival assay revealed that YM155 increased the sensitivity of NSCLC cells to gamma-radiation in vitro. The combination of YM155 and gamma-radiation induced synergistic increases both in the number of apoptotic cells and in the activity of caspase-3. Immunof luorescence analysis of histone gamma-H2AX also showed that YM155 delayed the repair of radiation-induced double-strand breaks in nuclear DNA. Finally, combination therapy with YM155 and gamma-radiation delayed the growth of NSCLC tumor xenografts in nude mice to a greater extent than did either treatment modality alone. Conclusions: These results suggest that YM155 sensitizes NSCLC cells to radiation both in vitro and in vivo, and that this effect of YM155 is likely attributable, at least in part, to the inhibition of DNA repair and enhancement of apoptosis that result from the down-regulation of survivin expression. Combined treatment with YM155 and radiation warrants investigation in clinical trials as a potential anticancer strategy.
  • Takeshi Yoshida; Isamu Okamoto; Takafumi Okabe; Tsutomu Iwasa; Taroh Satoh; Kazuto Nishio; Masahiro Fukuoka; Kazuhiko Nakagawa
    INTERNATIONAL JOURNAL OF CANCER WILEY-LISS 122 (7) 1530 - 1538 0020-7136 2008/04 [Refereed]
     
    Molecular inhibition of the epidermal growth factor receptor (EGFR) is a promising anticancer strategy, and monoclonal antibodies (mAbs) to EGFR are undergoing extensive evaluation in preclinical and clinical trials. However, the effects of anti-EGFR mAbs on EGFR signaling have remained unclear. We have now examined the effects of 2 anti-EGFR mAbs, matuzumab (EMD72000) and cetuximab (Erbitux), both of which are currently under assessment for treatment of various cancers, on EGFR signal transduction and cell survival in nonsmall cell lung cancer cell lines. Similar to EGF, matuzumab and cetuximab each induced phosphorylation of EGFR at several tyrosine phosphorylation sites as a result of receptor dimerization and activation of the receptor tyrosine kinase. In contrast to the effects of EGF, however, EGFR activation induced by these antibodies was not accompanied by receptor turnover or by activation of downstream signaling pathways that are mediated by Akt and Erk and are important for regulation of cell proliferation and survival. In addition, clonogenic survival assays revealed that matuzumab and cetuximab reduced the survival rate of H292 cells, in which they also inhibited the EGF-induced activation of Akt and Erk. Although we have examined only a few cell lines, our results indicate that the antitumor effects of matuzumab and cetuximab depend on inhibition of EGFR downstream signaling mediated by Akt or Erk rather than on inhibition of EGFR itself. (c) 2007 Wiley-Liss, Inc.
  • Takafumi Okabe; Isamu Okamoto; Sayaka Tsukioka; Junji Uchida; Tsutomu Iwasa; Takeshi Yoshida; Erina Hatashita; Yuki Yamada; Taroh Satoh; Kenji Tamura; Masahiro Fukuoka; Kazuhiko Nakagawa
    MOLECULAR CANCER THERAPEUTICS AMER ASSOC CANCER RESEARCH 7 (3) 599 - 606 1535-7163 2008/03 [Refereed]
     
    Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with the therapeutic response to EGFR tyrosine kinase inhibitors (TKI) in patients with advanced non-small cell lung cancer (NSCLC). The response rate to these drugs remains low, however, in NSCLC patients with wild-type EGFR alleles. Combination therapies with EGFR-TKIs and cytotoxic agents are considered a therapeutic option for patients with NSCLC expressing wild-type EGFR. We investigated the antiproliferative effect of the combination of the oral fluorouracil S-1 and the EGFR-TKI gefitinib in NSCLC cells of differing EGFR status. The combination of 5-fluorouracil and gefitinib showed a synergistic antiproliferative effect in vitro in all NSCLC cell lines tested. Combination chemotherapy with S-1 and gefitinib in vivo also had a synergistic antitumor effect on NSCLC xenografts regardless of the absence or presence of EGFR mutations. Gefitinib inhibited the expression of the transcription factor E2F-1, resulting in the down-regulation of thymidylate synthase at the mRNA and protein levels. These observations suggest that gefitinib-induced down-regulation of thymidylate synthase is responsible, at least in part, for the synergistic antitumor effect of combined treatment with S-1 and gefitinib and provide a basis for clinical evaluation of combination chemotherapy with S-1 and EGFR-TKIs in patients with solid tumors.
  • Y. Akashi; I. Okamoto; T. Iwasa; T. Yoshida; M. Suzuki; E. Hatashita; Y. Yamada; T. Satoh; M. Fukuoka; K. Ono; K. Nakagawa
    British Journal of Cancer 98 (4) 749 - 755 2008/02 [Refereed]
  • Tsutomu Iwasa; Yojiro Sadamoto; Soichi Itaba; Toshifumi Nasu; Yuji Ihara; Tadashi Misawa; Kazuhiko Nakamura
    Japanese Journal of Gastroenterology 104 (6) 804 - 808 0446-6586 2007/06 [Refereed]
     
    A 53-year-old man was admitted hospital because of frequent vomiting and poor digestion. Abdominal computed tomography showed a tumor, about 5 cm in diameter at the duodeno-jejunal junction. A barium contrast duodeno-small bowel series revealed stenosis in the therd portion, where push enteroscopy could not pass with normal mucosa. The preoperative diagnosis was submucosal or mesenteric tumor. Open surgery was performed. The tumor derived from the mesenterium and involved the anal side of the small intestine. The tumor was removed with partial excision of the upper jejunum. The diagnosis of mesenteric desmoid tumor was confirmed, histologically.
  • Y. Akashi; I. Okamoto; M. Suzuki; K. Tamura; T. Iwasa; S. Hisada; T. Satoh; K. Nakagawa; K. Ono; M. Fukuoka
    British Journal of Cancer 96 (10) 1532 - 1539 2007/05 [Refereed]

Conference Activities & Talks

  • Retrospective study of chemotherapy for elderly patients for breast cancer  [Not invited]
    Tsutomu Iwasa
    2018 Japanese Society of Medical Oncology Annual Meeting  2018/07
  • Phase II trial of Eribulin and S-1 combination therapy for advanced or recurrent breast cancer  [Not invited]
    Tsutomu Iwasa
    ESMO ASIA 2017  2017/11
  • Retrospective analysis of 74 breast cancer patients with Eribulin treatment  [Not invited]
    Tsutomu Iwasa
    2017 Japanese Society of Medical Oncology Annual Meetinng  2017/07
  • Phase I trial of Eribulin in combination with S-1 for advanced or recurrent breast cancer  [Not invited]
    Tsutomu Iwasa
    San Antonio Breast Cancer Symposium 2014  2014/12
  • 肺癌細胞株におけるIGF-1R 阻害剤 ＣＰ-751,871の放射線増感効果の検討  [Not invited]
    岩朝 勤; 岡本 勇; 畑下恵理奈; 山田友紀; 福岡正博; 中川 和彦
    第68回日本癌学会学術総会  2009/10  横浜  第68回日本癌学会学術総会
  • マツズマブはシスプラチンが誘導するＨＢ-ＥＧＦを介したＥＧＦＲシグナル伝達を抑制しシスプラチンの抗腫瘍効果を増強する  [Not invited]
    吉田 健史; 岡本 勇; 岩朝 勤; 福岡正博; 中川 和彦
    第67回日本癌学会学術総会  2008/10  名古屋  第67回日本癌学会学術総会
  • 肺癌細胞株におけるYM155の放射線感受性増強作用の検討  [Not invited]
    岩朝 勤; 岡本 勇; 畑下恵理奈; 山田友紀; 福岡正博; 中川 和彦
    第67回日本癌学会学術総会  2008/10  名古屋  第67回日本癌学会学術総会
  • Matuzumab and cetuximab activateb the epidermal growth factor receptor but fail to trigger downstream signaling by akt or erk  [Not invited]
    吉田 健史; 岡本 勇; 岡部崇記; 岩朝 勤; 佐藤 太郎; 西尾和人; 福岡正博; 中川 和彦
    A.A.C.R  2008/04  San Diego (U.S.A)  A.A.C.R
  • Radiosensitizing effect of YM155,a novel small molecule survivin suppressant, in non-small cell lung cancer cell lines  [Not invited]
    岩朝 勤; 岡本 勇; 佐藤 太郎; 福岡正博; 中川 和彦
    A.A.C.R  2008/04  San Diego (U.S.A)  A.A.C.R
  • Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling  [Not invited]
    吉田 健史; 岡本 勇; 岡部崇記; 岩朝 勤; 佐藤 太郎; 西尾和人; 福岡正博; 中川 和彦
    66th Annual Meeting of the Japanese Cancer Association  2007/10  横浜  66th Annual Meeting of the Japanese Cancer Association
  • EGFR抗体療法によるEGFR活性化と下流シグナル阻害  [Not invited]
    吉田 健史; 岡本 勇; 岡部崇記; 岩朝 勤; 佐藤 太郎; 西尾和人; 福岡正博; 中川 和彦
    第11回がん分子標的治療研究会総会  2007/07  大阪  第11回がん分子標的治療研究会総会
  • 肺癌細胞株におけるYM155の放射線感受性増強作用の検討  [Not invited]
    岩朝 勤; 岡本 勇; 佐藤 太郎; 福岡正博; 中川 和彦
    第11回がん分子標的治療研究会総会  2007/07  大阪  第11回がん分子標的治療研究会総会

MISC

  • 村田修一; 谷崎潤子; 岩朝勤; 黒崎隆; 田中薫; 林秀敏; 中川和彦; 濱有一郎  肺癌(Web)  63-  (3)  2023
  • Jun Masuda; Junji Tsurutani; Norikazu Masuda; Yuko Tanabe; Tsutomu Iwasa; Masato Takahashi; Manabu Futamura; Koji Matsumoto; Kenjiro Aogi; Hiroji Iwata; Mari Hosonaga; Toru Mukohara; Kenichi Yoshimura; Toshimi Takano  CANCER RESEARCH  81-  (4)  2021/02
  • Yukinori Ozaki; Shigehisa Kitano; Junji Tsurutani; Tsutomu Iwasa; Masato Takahashi; Toru Mukohara; Norikazu Masuda; Manabu Futamura; Hironobu Minami; Koji Matsumoto; Hidetaka Kawabata; Makiko Yamashita; Kenichi Yoshimura; Toshimi Takano  CANCER RESEARCH  81-  (4)  2021/02
  • 武田真幸; 武田真幸; 中川和彦; 林秀敏; 岩朝勤; 川上尚人; 渡邉諭美; 山本昇; 米盛勧; 小山隆文; 佐藤潤; 田村研治; 菊池圭一; 赤池健一郎; 竹田志保; 清水俊雄  日本癌治療学会学術集会(Web)  59th-  2021
  • 金村宙昌; 田中薫; 鈴木慎一郎; 黒崎隆; 磯本晃佑; 岩朝勤; 白石直樹; 林秀敏; 武田真幸; 中川和彦  気管支学  43-  2021
  • 西郷和真; 池川敦子; 木戸滋子; 川上尚人; 武田真幸; 岩朝勤; 巽純子; 福岡和也; 西尾和人; 田村和朗; 中川和彦; 松村謙臣  日本遺伝カウンセリング学会誌  41-  (4)  2021
  • Hiroaki Kato; Fumikata Hara; Masahiro Kitada; Masato Takahashi; Yuichiro Kikawa Yuichiro Kikawa; Eiko Sakata; Yoichi Naito; Yoshie Hasegawa; Tsuyoshi Saito; Tsutomu Iwasa; Junji Tsurutani; Naruto Taira; Tsutomu Takashima; Kosuke Kashiwabara; Tomohiko Aihara Tomohiko Aihara; Hirofumi Mukai  CANCER RESEARCH  80-  (4)  2020/02
  • Hiroko Masuda; Tsutomu Iwasa; Toru Mukohara; Shinya Tokunaga; Koji Matsumoto; Naoki Niikura; Yasuaki Sagara; Yasuo Miyoshi; Akihiko Shimomura; Masato Takahashi; Takeshi Nagashima; Mihoko Doi; Manabu Futamura; Kenichi Yoshimura; Toshimi Takano; Junji Tsurutani  CANCER RESEARCH  80-  (4)  2020/02
  • Jun Masuda; Junji Tsurutani; Norikazu Masuda; Manabu Futamura; Koji Matsumoto; Kenjiro Aogi; Masato Takahashi; Hiroji Iwata; Tsutomu Iwasa; Toru Mukohara; Kenichi Yoshimura; Takayuki Ueno; Toshimi Takano  CANCER RESEARCH  80-  (4)  2020/02
  • 実臨床におけるリキッドバイオプシーの役割 CAPP-Seqを用いたLiquid biopsyによるT790M陽性非小細胞肺癌のオシメルチニブ耐性因子の検討
    加藤 了資; 林 秀敏; 米阪 仁雄; 原谷 浩司; 酒井 瞳; 高濱 隆幸; 岩朝 勤; 田中 薫; 吉田 健史; 武田 真幸; 金田 裕靖; 清水 重喜; 坂井 和子; 伊藤 彰彦; 西尾 和人; 中川 和彦  肺癌  59-  (6)  575  -575  2019/11
  • Masayuki Takeda; Kazuko Sakai; Shigeki Shimizu; Takayuki Takahama; Takeshi Yoshida; Satomi Watanabe; Tsutomu Iwasa; Kimio Yonesaka; Shinichiro Suzuki; Hidetoshi Hayashi; Hisato Kawakami; Yoshikane Nonagase; Kaoru Tanaka; Junji Tsurutani; Kazumasa Saigo; Akihiko Ito; Tetsuya Mitsudomi; Kazuhiko Nakagawa; Kazuto Nishio  CANCER RESEARCH  79-  (13)  2019/07
  • パルボシクリブによる好中球減少症を経験した28症例から考えた至適容量の検討
    広川 恵寿輝; 岩朝 勤; 酒井 瞳; 渡邊 諭美; 菰池 佳史; 中川 和彦  日本乳癌学会総会プログラム抄録集  27回-  373  -373  2019/07
  • HER2陽性乳癌細胞株における抗HER3抗体パトリツマブと抗HER2抗体トラスツズマブ/ペルツズマブの3剤併用治療
    渡邉 諭美; 鶴谷 純司; 広川 恵寿輝; 酒井 瞳; 岩朝 勤; 中川 和彦  日本乳癌学会総会プログラム抄録集  27回-  539  -539  2019/07
  • DAS59を用いたがん治療による外見変化の心理社会的影響と情報ニーズ・ケアニーズの実態調査
    酒井 瞳; 名倉 美樹; 保田 紀子; 岩朝 勤; 渡邊 諭美; 林 真紀子; 遠藤 美幸; 菰池 佳史; 小山 敦子; 中川 和彦  日本乳癌学会総会プログラム抄録集  27回-  554  -554  2019/07
  • 化学療法後の分子標的治療薬の奏効に関する検討
    岩朝 勤; 広川 恵寿輝; 酒井 瞳; 渡邊 諭美; 東 千尋; 田中 由美子; 新崎 亘; 橋本 幸彦; 菰池 佳文; 中川 和彦  日本乳癌学会総会プログラム抄録集  27回-  608  -608  2019/07
  • Fumikata Hara; Masahiro Kitada; Masato Takahashi; Yuichiro Kikawa; Hiroaki Kato; Eiko Sakata; Yoichi Naito; Yoshie Hasegawa; Tsuyoshi Saito; Tsutomu Iwasa; Junji Tsurutani; Naruto Taira; Tsutomu Takashima; Kosuke Kashiwabara; Tomohiko Aihara; Hirofumi Mukai  JOURNAL OF CLINICAL ONCOLOGY  37-  (15)  2019/05
  • 当院におけるオシメルチニブの使用成績と血漿中cfDNAの有用性に関する検討
    加藤 了資; 林 秀敏; 米阪 仁雄; 原谷 浩司; 酒井 瞳; 高濱 隆幸; 谷崎 潤子; 岩朝 勤; 田中 薫; 吉田 健史; 武田 真幸; 金田 裕靖; 中川 和彦; 清水 重喜; 伊藤 彰彦; 坂井 和子; 西尾 和人  肺癌  59-  (2)  194  -194  2019/04
  • 加藤了資; 林秀敏; 米阪仁雄; 原谷浩司; 酒井瞳; 高濱隆幸; 谷崎潤子; 岩朝勤; 田中薫; 吉田健史; 武田真幸; 金田裕靖; 中川和彦; 清水重喜; 伊藤彰彦; 坂井和子; 西尾和人  肺癌(Web)  59-  (2)  2019
  • 高濱 隆幸; 武田 真幸; 林 秀敏; 米阪 仁雄; 田中 薫; 岩朝 勤; 吉田 健史; 原谷 浩司; 加藤 了資; 鈴木 慎一郎  肺癌  58-  (6)  699  -699  2018/10
  • 加藤 了資; 林 秀敏; 米阪 仁雄; 原谷 浩司; 酒井 瞳; 高濱 隆幸; 谷崎 潤子; 岩朝 勤; 田中 薫; 吉田 健史; 武田 真幸; 金田 裕靖; 清水 重喜; 坂井 和子; 伊藤 彰彦; 西尾 和人; 中川 和彦  肺癌  58-  (6)  519  -519  2018/10
  • 岩朝 勤; 鶴谷 純司  腫瘍内科 = Clinical oncology  22-  (3)  260  -266  2018/09
  • 【期待される新薬-分子標的治療薬の効果と副作用】 小分子薬 オラパリブ、ルカパリブ(PARP阻害薬)
    岩朝 勤  腫瘍内科  21-  (6)  691  -697  2018/06
  • 田中 薫; 加藤 了資; 高濱 隆幸; 谷崎 潤子; 岩朝 勤; 林 秀敏; 武田 真幸; 中川 和彦  気管支学  40-  (Suppl.)  S239  -S239  2018/05
  • Phase II trial of Eribulin/S-1 combination therapy for advanced/recurrent breast cancer(和訳中)
    鶴谷 純司; 岩朝 勤; 水野 豊; 小島 康幸; 高島 勉; 松並 展輝; 森本 卓; 山村 順; 大谷 彰一郎; 田辺 裕子; 渡邉 諭美; 加藤 了資; 高野 利美; 菰池 佳史; 中川 和彦  日本乳癌学会総会プログラム抄録集  26回-  334  -334  2018/05
  • 乳癌化学療法による外見変化に対する医師の認識と介入の実態調査
    酒井 瞳; 岩朝 勤; 鶴谷 純司; 菰池 佳史  日本乳癌学会総会プログラム抄録集  26回-  363  -363  2018/05
  • 当院における高齢者への化学療法施行の現状に関して
    岩朝 勤; 鶴谷 純司; 酒井 瞳; 渡邊 諭美; 新崎 亘; 安積 達也; 橋本 幸彦; 菰池 佳史  日本乳癌学会総会プログラム抄録集  26回-  532  -532  2018/05
  • 初発骨転移症例の予後規定因子の検討
    菰池 佳史; 東 千尋; 田中 裕美子; 濱田 未佳; 新崎 亘; 橋本 幸彦; 北條 敏也; 乾 浩己; 鶴谷 純司; 岩朝 勤; 酒井 瞳; 大和 宗久; 金泉 博文; 山村 順  日本乳癌学会総会プログラム抄録集  26回-  636  -636  2018/05
  • Shamu Modi; Junji Tsurutani; Shunji Takahashi; Hiroji Iwata; Haeseong Park; Charles H. Redfern; Toshihiko Doi; Bob Li; Tsutomu Iwasa; Shunichiro Taira; Masaya Hattori; Cynthia X. Ma; Jennifer M. Fisher; Yoichi Naito; Kan Yonemori; Yui Kawasaki; Kaku Saito; Takahiro Jikoh; Javad Shahidi; Caleb C. Lee; Antoine Yver; Kenji Tamura  CANCER RESEARCH  78-  (4)  2018/02
  • 酒井 瞳; 岩朝 勤; 菰池 佳史; 鶴谷 純司; 坂井 和子; 西尾 和人; 中川 和彦  日本乳癌学会総会プログラム抄録集  25回-  301  -301  2017/07
  • 乳癌における原発腫瘍と脳転移腫瘍の免疫微小環境の変化
    新倉 直樹; 扇屋 りん; 熊木 伸枝; 八十島 宏行; 岩朝 勤; 神林 智寿子; 大下内 理紗; 常泉 道子; 渡邊 健一; 松井 哲; 藤澤 知巳; 佐治 重衡; 徳田 裕; 増田 慎三; 岩田 広治  日本乳癌学会総会プログラム抄録集  25回-  261  -261  2017/07
  • T-DM1 de novo耐性HER2陽性乳癌の臨床病理学的検討
    酒井 瞳; 岩朝 勤; 菰池 佳史; 鶴谷 純司; 坂井 和子; 西尾 和人; 中川 和彦  日本乳癌学会総会プログラム抄録集  25回-  301  -301  2017/07
  • 安積 達也; 東 千尋; 金泉 博文; 久保田 倫代; 濱田 未佳; 藤島 成; 新崎 亘; 酒井 瞳; 岩朝 勤; 鶴谷 純司; 橋本 幸彦; 乾 浩己; 北條 敏也; 大和 宗久; 金森 修一; 菰池 佳史  日本乳癌学会総会プログラム抄録集  25回-  312  -312  2017/07
  • 橋本 幸彦; 東 千尋; 金泉 博文; 濱田 未佳; 新崎 亘; 安積 達也; 乾 浩己; 北條 敏也; 大和 宗久; 酒井 瞳; 岩朝 勤; 鶴谷 純司; 金森 修一; 菰池 佳史  日本乳癌学会総会プログラム抄録集  25回-  349  -349  2017/07
  • 岩朝 勤; 鶴谷 純司; 酒井 瞳; 渡邊 諭美; 新崎 亘; 安積 達也; 橋本 幸彦; 菰池 佳史; 中川 和彦  日本乳癌学会総会プログラム抄録集  25回-  403  -403  2017/07
  • 東 千尋; 金泉 博文; 濱田 未佳; 新崎 亘; 安積 達也; 橋本 幸彦; 乾 浩己; 北條 敏也; 大和 宗久; 菰池 佳史; 酒井 瞳; 岩朝 勤; 鶴谷 純司  日本乳癌学会総会プログラム抄録集  25回-  425  -425  2017/07
  • 金泉 博文; 東 千尋; 濱田 未佳; 新崎 亘; 安積 達也; 橋本 幸彦; 乾 浩己; 北条 敏也; 大和 宗久; 酒井 瞳; 岩朝 勤; 鶴谷 純司; 菰池 佳史  日本乳癌学会総会プログラム抄録集  25回-  512  -512  2017/07
  • 菰池 佳史; 松岡 梓; 東 千尋; 金泉 博文; 濱田 未佳; 新崎 亘; 安積 達也; 橋本 幸彦; 乾 浩己; 北條 敏也; 大和 宗久; 酒井 瞳; 岩朝 勤; 鶴谷 純司; 金森 修一  日本乳癌学会総会プログラム抄録集  25回-  675  -675  2017/07
  • osimertinibが奏効したEGFR T790M変異陽性肺腺癌、癌性髄膜炎の1例
    酒井 瞳; 林 秀敏; 岩朝 勤; 武田 真幸; 中川 和彦  肺癌  57-  (3)  242  -242  2017/06
  • 組織型転化を来したEGFR陽性肺癌症例の臨床的検討
    田中 薫; 加藤 了資; 原谷 浩司; 武川 直樹; 高濱 隆幸; 岩朝 勤; 林 秀敏; 武田 真幸; 中川 和彦; 清水 重喜; 伊藤 彰彦  肺癌  57-  (3)  243  -244  2017/06
  • 皮膚筋炎合併の胸腺癌患者に対する全人的苦痛の緩和に務めた1例
    河野 恵; 岩朝 勤; 中西 良子; 森田 さやか; 徳留 由貴; 川上 尚人; 吉田 健史; 三瀬 博之; 宮崎 巳美; 尾崎 公俊  肺癌  57-  (3)  250  -251  2017/06
  • 進行非小細胞肺癌に対する微量心嚢水の予後に関する検討
    加藤 了資; 林 秀敏; 酒井 瞳; 原谷 浩司; 高濱 隆幸; 岩朝 勤; 田中 薫; 武田 真幸; 中川 和彦; 千葉 康敬  肺癌  57-  (3)  253  -253  2017/06
  • Toshihiko Doi; Hiroji Iwata; Junji Tsurutani; Shunji Takahashi; Haeseong Park; Charles H. Redfern; Kohei Shitara; Chikako Shimizu; Hiroya Taniguchi; Tsutomu Iwasa; Shinichiro Taira; Albert C. Lockhart; Jennifer M. Fisher; Takahiro Jikoh; Yoshihiko Fujisaki; Caleb C. Lee; Antoine Yver; Kenji Tamura  JOURNAL OF CLINICAL ONCOLOGY  35-  2017/05
  • 免疫Checkpoint阻害剤で汎下垂体機能不全を来した悪性黒色腫の1例
    奥野 達哉; 酒井 瞳; 武友 保憲; 岩朝 勤; 田中 薫; 武田 真幸; 鶴谷 純司; 田村 孝雄; 池上 博司; 中川 和彦  日本内科学会雑誌  106-  (Suppl.)  233  -233  2017/02
  • 岩朝勤; 鶴谷純司; 酒井瞳; 渡邉諭美; 新崎亘; 安積達也; 橋本幸彦; 菰池佳史; 中川和彦  日本臨床腫瘍学会学術集会(CD-ROM)  15th-  2017
  • 奥野達哉; 酒井瞳; 武友保憲; 岩朝勤; 田中薫; 武田真幸; 鶴谷純司; 田村孝雄; 池上博司; 中川和彦  日本臨床腫瘍学会学術集会(CD-ROM)  15th-  ROMBUNNO.P1‐010  2017
  • ニボルマブ投与でpseudoprogressionを認めた肺腺癌の2例
    谷崎 潤子; 林 秀敏; 田中 薫; 岩朝 勤; 武田 真幸; 中川 和彦  肺癌  56-  (7)  1067  -1067  2016/12
  • 尿崩症を初発症状とした肺小細胞癌下垂体転移の1例
    加藤 了資; 酒井 瞳; 原谷 浩司; 高濱 隆幸; 谷崎 潤子; 吉田 健史; 岩朝 勤; 田中 薫; 林 秀敏; 武田 真幸; 中川 和彦; 古川 健太郎; 奥田 武司  肺癌  56-  (7)  1072  -1072  2016/12
  • 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定
    武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 吉田 健史; 岩朝 勤; 高濱 隆幸; 野長瀬 祥兼; 西尾 和人; 中川 和彦  近畿大学医学雑誌  41-  (3-4)  19A  -19A  2016/12
  • 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定
    武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 吉田 健史; 岩朝 勤; 高濱 隆幸; 野長瀬 祥兼; 西尾 和人; 中川 和彦  近畿大学医学雑誌  41-  (3-4)  19A  -19A  2016/12
  • ニボルマブ投与でpseudoprogressionを認めた肺腺癌の2例
    谷崎 潤子; 林 秀敏; 田中 薫; 岩朝 勤; 武田 真幸; 中川 和彦  肺癌  56-  (7)  1067  -1067  2016/12
  • 尿崩症を初発症状とした肺小細胞癌下垂体転移の1例
    加藤 了資; 酒井 瞳; 原谷 浩司; 高濱 隆幸; 谷崎 潤子; 吉田 健史; 岩朝 勤; 田中 薫; 林 秀敏; 武田 真幸; 中川 和彦; 古川 健太郎; 奥田 武司  肺癌  56-  (7)  1072  -1072  2016/12
  • FGFR T790M変異陽性肺腺癌、癌性髄膜炎にosimertinibを投与した1例
    酒井 瞳; 林 秀敏; 岩朝 勤; 武田 真幸; 中川 和彦  肺癌  56-  (7)  1077  -1077  2016/12
  • 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定
    武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 吉田 健史; 岩朝 勤; 高濱 隆幸; 野長瀬 祥兼; 西尾 和人; 中川 和彦  肺癌  56-  (6)  637  -637  2016/11
  • 酒井 瞳; 岩朝 勤  臨床腫瘍プラクティス  12-  (4)  308  -311  2016/11
  • 谷崎 潤子; 林 秀敏; 加藤 了資; 原谷 浩司; 高濱 隆幸; 田中 薫; 岩朝 勤; 武田 真幸; 中川 和彦  肺癌  56-  (6)  569  -569  2016/11
  • 田中 薫; 谷崎 潤子; 加藤 了資; 原谷 浩司; 武川 直樹; 高濱 隆幸; 岩朝 勤; 林 秀敏; 武田 真幸; 中川 和彦  肺癌  56-  (6)  572  -572  2016/11
  • 武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 吉田 健史; 岩朝 勤; 高濱 隆幸; 野長瀬 祥兼; 西尾 和人; 中川 和彦  肺癌  56-  (6)  637  -637  2016/11
  • 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定
    武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 高濱 隆幸; 吉田 健史; 岩朝 勤; 光冨 徹哉; 伊藤 彰彦; 西尾 和人; 中川 和彦  日本癌学会総会記事  75回-  J  -1063  2016/10
  • 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定
    武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 高濱 隆幸; 吉田 健史; 岩朝 勤; 光冨 徹哉; 伊藤 彰彦; 西尾 和人; 中川 和彦  日本癌学会総会記事  75回-  J  -1063  2016/10
  • イワサ ツトム; ツルタニ ジュンジ  腫瘍内科 = Clinical oncology / 腫瘍内科編集委員会 編  18-  (3)  220  -225  2016/09
  • 岩朝 勤; 鶴谷 純司  腫瘍内科  18-  (3)  220  -225  2016/09
  • 子育て世代のがん患者と家族への終末期ケアにおける予期悲嘆への関わりが困難だった一症例
    徳留 由貴; 宮崎 巳美; 吉田 利恵; 高山 温子; 河野 恵; 尾崎 公俊; 三瀬 博之; 吉田 健史; 岩朝 勤  Palliative Care Research  11-  (Suppl.)  S531  -S531  2016/06
  • WATANABE Satomi; TAKEDA Masayuki; TAKAHAMA Takayuki; TANIZAKI Junko; IWASA Tsutomu; TSURUTANI Junji; HAYASHI Hidetoshi; SHIMIZU Toshio; WADA Yoshitaka; NAKAGAWA Kazuhiko  日本臨床腫瘍学会学術集会(CD-ROM)  14th-  ROMBUNNO.PF1‐045  2016
  • 加藤了資; 酒井瞳; 原谷浩司; 高濱隆幸; 谷崎潤子; 吉田健史; 岩朝勤; 田中薫; 林秀敏; 武田真幸; 中川和彦; 古川健太郎; 奥田武司  肺癌(Web)  56-  (7)  1072(J‐STAGE)  2016
  • 谷崎潤子; 林秀敏; 田中薫; 岩朝勤; 武田真幸; 中川和彦  肺癌(Web)  56-  (7)  1067(J‐STAGE)  2016
  • Hiroyasu Kaneda; Satomi Nishida; Tsutomu Iwasa; Toshio Shimizu; Kazuya Fukuoka; Kazuhiko Nakagawa  ANNALS OF ONCOLOGY  26-  126  -126  2015/11
  • Tsutomu Iwasa; Kazuhiko Nakagawa; Junji Tsurutani; Satomi Nishida; Yoshifumi Komoike; Yukihiko Hashimoto; Tatsuya Azumi; Wataru Shinzaki  ANNALS OF ONCOLOGY  26-  127  -127  2015/11
  • Clinical benefit of continued therapy with crizotinib beyond initial progression in ALK + NSCLC(和訳中)
    金田 裕靖; 武田 真幸; 田中 薫; 吉田 健史; 岩朝 勤; 岡本 邦男; 高濱 隆幸; 清水 俊雄; 中川 和彦  肺癌  55-  (5)  466  -466  2015/10
  • 金田 裕靖; 武田 真幸; 田中 薫; 吉田 健史; 岩朝 勤; 岡本 邦男; 高濱 隆幸; 清水 俊雄; 中川 和彦  肺癌  55-  (5)  466  -466  2015/10
  • 田中 薫; 西田 諭美; 原谷 浩司; 野長瀬 祥兼; 高濱 隆幸; 吉田 健史; 岩朝 勤; 林 秀敏; 武田 真幸; 金田 裕靖; 中川 和彦  肺癌  55-  (5)  547  -547  2015/10
  • 武川 直樹; 中川 和彦; 鶴谷 純司; 清水 俊雄; 武田 真幸; 田中 薫; 岩朝 勤; 吉田 健史; 林 秀敏; 谷崎 潤子; 高濱 隆幸; 原谷 浩司; 西田 諭美  肺癌  55-  (5)  661  -661  2015/10
  • 田中 薫; 西田 諭美; 原谷 浩司; 野長瀬 祥兼; 高濱 隆幸; 吉田 健史; 岩朝 勤; 林 秀敏; 武田 真幸; 金田 裕靖; 中川 和彦  気管支学 : 日本気管支研究会雑誌  37-  (5)  2015/09
  • 田中 薫; 西田 諭美; 原谷 浩司; 野長瀬 祥兼; 高濱 隆幸; 吉田 健史; 岩朝 勤; 林 秀敏; 武田 真幸; 金田 裕靖; 中川 和彦  気管支学  37-  (5)  607  -607  2015/09
  • 当院における非小細胞肺癌に対するre-biopsyの検討
    田中 薫; 西田 諭美; 原谷 浩司; 野長瀬 祥兼; 高濱 隆幸; 吉田 健史; 岩朝 勤; 林 秀敏; 武田 真幸; 中川 和彦; 金田 裕靖  肺癌  55-  (4)  306  -307  2015/08
  • 肺癌における次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定
    谷崎 潤子; 武田 真幸; 清水 俊雄; 金田 裕靖; 田中 薫; 岩朝 勤; 吉田 健史; 高濱 隆幸; 中川 和彦; 坂井 和子; 西尾 和人  肺癌  55-  (4)  311  -311  2015/08
  • Alectinibによる治療後に小細胞肺癌・扁平上皮癌への形質転換を認めたALK融合遺伝子陽性肺癌の1例
    高濱 隆幸; 林 秀敏; 武川 直樹; 植田 勲人; 吉田 健史; 岩朝 勤; 田中 薫; 武田 真幸; 中川 和彦  肺癌  55-  (4)  316  -316  2015/08
  • 長島 由紀子; 安積 達也; 岩朝 勤; 鶴谷 純司; 中川 和彦; 前田 和成; 前田 訓子; 山本 滋; 岡 正朗  日本乳癌学会総会プログラム抄録集  23回-  302  -302  2015/07
  • 岩朝 勤; 西田 諭美; 鶴谷 純司; 中川 和彦; 新崎 亘; 安積 達也; 橋本 幸彦; 菰池 佳史  日本乳癌学会総会プログラム抄録集  23回-  328  -328  2015/07
  • 松並 展輝; 阿部 元; 鶴谷 純司; 岩朝 勤; 森島 宏隆; 小田 直文; 玉川 孝治; 谷島 裕之; 神垣 俊二; 山村 順; 稲治 英生; 西 敏夫; 中野 芳明; 荻野 信夫; 山崎 圭一; 菰池 佳史; 手塚 健志; 新田 敏勝; 平井 昭彦; 中川 和彦; 南大阪乳癌診療ネットワーク; SON  日本乳癌学会総会プログラム抄録集  23回-  399  -399  2015/07
  • 安積 達也; 久保田 倫代; 濱田 未佳; 新崎 亘; 藤島 成; 橋本 幸彦; 乾 浩己; 北條 敏也; 大和 宗久; 西田 諭美; 岩朝 勤; 鶴谷 純司; 金森 修一; 菰池 佳史  日本乳癌学会総会プログラム抄録集  23回-  645  -645  2015/07
  • イワサ ツトム; ツルタニ ジュンジ  腫瘍内科 = Clinical oncology / 腫瘍内科編集委員会 編  15-  (5)  450  -457  2015/05
  • Tsutomu Iwasa; Junji Tsurutani; Satomi Nishida; Yoshifumi Komoike; Kazuhiko Nakagawa  CANCER RESEARCH  75-  2015/05
  • 岩朝 勤; 鶴谷 純司  腫瘍内科  15-  (5)  450  -457  2015/05
  • 武田 真幸; 坂井 和子; 田中 薫; 吉田 健史; 岩朝 勤; 高濱 隆幸; 野長瀬 祥兼; 岡部 崇記; 林 秀敏; 岡本 邦男; 金田 裕靖; 清水 俊雄; 西尾 和人; 中川 和彦  日本呼吸器学会誌  4-  (増刊)  146  -146  2015/03
  • EGFR遺伝子変異陽性非小細胞肺癌に対するerlotinibの初回治療における有用性の検討
    西田 諭美; 金田 裕靖; 工藤 慶太; 高濱 隆幸; 岩朝 勤; 田中 薫; 吉田 健史; 武田 真幸; 清水 俊雄; 中川 和彦  日本内科学会雑誌  104-  (Suppl.)  191  -191  2015/02
  • 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定
    武田 真幸; 清水 俊雄; 金田 裕靖; 田中 薫; 岩朝 勤; 吉田 健史; 高濱 隆幸; 坂井 和子; 西尾 和人; 中川 和彦  日本内科学会雑誌  104-  (Suppl.)  236  -236  2015/02
  • 化学療法中に間質性肺炎増悪を来した肺癌患者転帰の後ろ向き検討
    高濱 隆幸; 金田 裕靖; 田中 薫; 工藤 慶太; 岩朝 勤; 吉田 健史; 武田 真幸; 清水 俊雄; 鶴谷 純司; 中川 和彦  日本内科学会雑誌  104-  (Suppl.)  242  -242  2015/02
  • 再発進行乳癌におけるエリブリンとTS-1療法の検討
    岩朝 勤; 西田 諭美; 田中 薫; 工藤 慶太; 吉田 健史; 武田 真幸; 金田 裕靖; 清水 俊雄; 鶴谷 純司; 中川 和彦  日本内科学会雑誌  104-  (Suppl.)  284  -284  2015/02
  • EGFR-TKI既治療のEGFR遺伝子変異陽性NSCLCに対してアファチニブを使用した1例
    西田 諭美; 工藤 慶太; 金田 裕靖; 高濱 隆幸; 岩朝 勤; 田中 薫; 吉田 健史; 武田 真幸; 清水 俊雄; 中川 和彦  肺癌  55-  (1)  71  -71  2015/02
  • 谷崎潤子; 武田真幸; 清水俊雄; 金田裕靖; 田中薫; 岩朝勤; 吉田健史; 高濱隆幸; 中川和彦; 坂井和子; 西尾和人  肺癌(Web)  55-  (4)  2015
  • 西田諭美; 工藤慶太; 金田裕靖; 高濱隆幸; 岩朝勤; 田中薫; 吉田健史; 武田真幸; 清水俊雄; 中川和彦  肺癌(Web)  55-  (1)  71(J‐STAGE)  2015
  • 高濱隆幸; 林秀敏; 武川直樹; 植田勲人; 吉田健史; 岩朝勤; 田中薫; 武田真幸; 中川和彦  肺癌(Web)  55-  (4)  316(J‐STAGE)  2015
  • 宮川 知保; 田中 薫; 西田 諭美; 野長瀬 祥兼; 高濱 隆幸; 吉田 健史; 岩朝 勤; 工藤 慶太; 武田 真幸; 金田 裕靖; 鶴谷 純司; 中川 和彦  気管支学  37-  (1)  114  -115  2015
  • 清水 俊雄; 瀬戸 貴司; 平井 文彦; 竹中 朋祐; 鶴谷 純司; 金田 裕靖; 岩朝 勤; 川上 尚人; 野口 一夫; 嶋本 隆司; 中川 和彦  肺癌  54-  (5)  352  -352  2014/10
  • 武田 真幸; 清水 俊雄; 田中 薫; 吉田 健史; 岩朝 勤; 高濱 隆幸; 野長瀬 祥兼; 岡部 崇記; 林 秀敏; 岡本 邦男; 坂井 和子; 西尾 和人; 中川 和彦  肺癌  54-  (5)  364  -364  2014/10
  • 西田 諭美; 金田 裕靖; 工藤 慶太; 田中 薫; 吉田 健史; 岩朝 勤; 高濱 隆幸; 武田 真幸; 清水 俊雄; 中川 和彦  肺癌  54-  (5)  460  -460  2014/10
  • 中田 有紀; 高濱 隆幸; 田中 薫; 植田 勲人; 西田 論美; 武川 直樹; 野長瀬 祥兼; 工藤 慶太; 岩朝 勤; 吉田 健史; 武田 真幸; 金田 裕靖; 清水 俊雄; 鶴谷 純司; 田村 孝雄; 中川 和彦  肺癌  54-  (5)  506  -506  2014/10
  • 高濱 隆幸; 金田 裕靖; 田中 薫; 植田 勲人; 西田 諭美; 武川 直樹; 野長瀬 祥兼; 工藤 慶太; 岩朝 勤; 吉田 健史; 武田 真幸; 清水 俊雄; 鶴谷 純司; 田村 孝雄; 中川 和彦  肺癌  54-  (5)  587  -587  2014/10
  • 鶴谷 純司; 黒井 克昌; 佐伯 俊昭; 宮崎 昌樹; 仁科 慎一; 牧村 ちひろ; 谷崎 潤子; 岡本 邦男; 岩朝 勤; 菰池 佳史; 山下 年成; 有賀 智之; 重川 崇; 中川 和彦  日本乳癌学会総会プログラム抄録集  22回-  287  -287  2014/07
  • 岩朝 勤; 鶴谷 純司; 中川 和彦; 菰池 佳史; 橋本 幸彦; 安積 達也; 新崎 亘  日本乳癌学会総会プログラム抄録集  22回-  436  -436  2014/07
  • 岩朝 勤; 鶴谷 純司  臨床腫瘍プラクティス  10-  (2)  252  -256  2014/05
  • K. Kuroi; J. Tsurutani; T. Yamashita; T. Aruga; T. Shigekawa; M. Miyazaki; S. Nishina; C. Makimura; J. Tanizaki; K. Okamoto; T. Iwasa; Y. Komoike; K. Nakagawa; T. Saeki  CANCER RESEARCH  73-  2013/12
  • T. Iwasa; J. Tsurutani; H. Matsuoka; K. Okamoto; T. Shimizu; T. Kurata; K. Nakagawa; T. Azumi; Y. Hashimoto; Y. Komoike  ANNALS OF ONCOLOGY  24-  36  -36  2013/11
  • 岩朝 勤; 中川 和彦  腫瘍内科  12-  (2)  175  -184  2013/08
  • 岩朝 勤; 鶴谷 純司  腫瘍内科  12-  (1)  30  -38  2013/07
  • 【治療に伴う看護特集 いつごろ生じる?看護はどうする?がひとめでわかる がん化学療法の副作用速習おぼえ書き】 静脈炎
    岩朝 勤  プロフェッショナルがんナーシング  3-  (3)  264  -265  2013/06
  • 岩朝勤; 鶴谷純司; 松岡弘道; 岡本邦男; 清水俊雄; 倉田宝保; 中川和彦; 安積達也; 橋本幸彦; 菰池佳史  日本臨床腫瘍学会学術集会(CD-ROM)  11th-  2013
  • 岩朝 勤; 中川 和彦  腫瘍内科  11-  (1)  100  -105  2013/01
  • がん診療連携拠点病院緩和ケアチームへの非常勤精神科医師のかかわり
    平野 勇生; 東 睦広; 木下 貴裕; 厚坊 浩史; 井上 明美; 岩朝 勤; 辰己 晃造  日本医療マネジメント学会雑誌  11-  (Suppl.)  368  -368  2010/06
  • CP-751,871によるインスリン様成長因子-1受容体の抑制は非小細胞肺癌細胞の放射線感受性を増大させる(Inhibition of insulin-like growth factor-1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells)
    岩朝 勤; 岡本 勇; 鈴木 実; 畑下 恵理奈; 山田 友紀; 福岡 正博; 小野 公二; 中川 和彦  日本癌学会総会記事  68回-  79  -79  2009/08
  • 岩朝 勤; 岡本 勇  Clinical oncology  2-  (6)  542  -548  2008/12
  • IGF-1R阻害剤
    岩朝 勤; 岡本 勇  腫瘍内科  2-  (6)  542  -548  2008/12
  • 肺癌細胞株におけるYM155の放射線感受性増強作用の検討(Radiosensitizing effect of YM155, a novel small molecule survivin suppressant, in non small cell lung cancer cell lines)
    岩朝 勤; 岡本 勇; 鈴木 実; 中原 崇人; 山中 堅太郎; 畑下 恵理菜; 山田 友紀; 福岡 正博; 小野 公二; 中川 和彦  日本癌学会総会記事  67回-  53  -53  2008/09
  • マツズマブはシスプラチンが誘導するHB-EGFを介したEGFRシグナル伝達を抑制しシスプラチンの抗腫瘍効果を増強する(Matuzumab enhances the antitumor effect of CDDP and blocks CDDP-induced activation of EGFR signaling mediated by HB-EGF)
    吉田 健史; 岡本 勇; 岩朝 勤; 福岡 正博; 中川 和彦  日本癌学会総会記事  67回-  151  -151  2008/09
  • ヒト肺癌細胞株におけるS-1とゲフィチニブの併用効果の検討
    岡部 崇記; 岡本 勇; 月岡 清夏; 内田 淳二; 岩朝 勤; 吉田 健史; 畑下 恵理奈; 山田 友紀; 佐藤 太郎; 田村 研治; 福岡 正博; 中川 和彦  肺癌  48-  (2)  150  -150  2008/04
  • 新規抗癌剤TZT-1027の放射線増感性について(The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo)
    明石 雄策; 岡本 勇; 鈴木 実; 田村 研治; 岩朝 勤; 佐藤 太郎; 福岡 正博; 小野 公二; 中川 和彦  日本癌学会総会記事  66回-  278  -278  2007/08
  • 分子標的としてのEGF受容体 Matuzumabとcetuximabは表皮成長因子受容体を活性化するが下流シグナル伝達を誘発しない(EGF Receptor as a Molecular Target Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling)
    吉田 健史; 岡本 勇; 岡部 崇記; 岩朝 勤; 佐藤 太郎; 西尾 和人; 福岡 正博; 中川 和彦  日本癌学会総会記事  66回-  411  -411  2007/08
  • 膵癌手術10年後に転移性肺腫瘍として診断された1例
    岩朝 勤; 梁 尚志; 米阪 仁雄; 末岐 博文; 有馬 良一  肺癌  46-  (2)  179  -179  2006/04
  • 当院における非小細胞肺癌に対する術後補助化学療法としてのカルボプラチンとパクリタキセルの併用療法について
    米阪 仁雄; 梁 尚志; 岩朝 勤; 末岐 博文; 有馬 良一  肺癌  46-  (2)  180  -180  2006/04
  • Pleomorphic carcinomaの1例
    市堀 泰裕; 梁 尚志; 米阪 仁雄; 岩朝 勤; 末岐 博文; 有馬 良一  肺癌  46-  (2)  186  -187  2006/04
  • 当院における肺癌に伴った癌性心膜炎の検討
    米阪 仁雄; 岩朝 勤; 梁 尚志; 末岐 博文; 有馬 良一; 福岡 正博  肺癌  45-  (5)  652  -652  2005/11
  • 十二指腸下行脚に発生しクリップにて内視鏡的に止血しえたDieulafoy潰瘍の2例
    西林 宏之; 市堀 泰裕; 金城 聖一; 清水 憲政; 池田 妙; 白井 威人; 有吉 隆久; 宮部 欽生; 岩朝 勤; 今西 和雄; 猪股 有紀子; 薮内 以和夫; 西川 嘉郎; 西村 典子; 久米 郁代; 石本 久美子; 久山 純  共済医報  54-  (Suppl.)  140  -140  2005/10
  • 当院における癌性心外膜炎の検討
    岩朝 勤; 梁 尚志; 米阪 仁雄; 末岐 博文; 有馬 良一; 明石 雄策  肺癌  45-  (1)  93  -93  2005/02
  • 後縦原発の悪性リンパ腫の1例
    米阪 仁雄; 梁 尚志; 岩朝 勤; 末岐 博文; 有馬 良一  肺癌  45-  (1)  97  -97  2005/02
  • 末梢肺発生のAdenoid cystic carcinomaの1例
    末岐 博文; 梁 尚志; 米阪 仁雄; 岩朝 勤; 有馬 良一  肺癌  45-  (1)  98  -98  2005/02

Committee Membership

  • 2022/07 - Today   Japanese Breast Cancer Society   Councilor

Other link

researchmap


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.